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Abstract
Predicting Opioid Prescribing Behaviors:
Influence of an Expert Opioid-Risk Evaluation
Alison M. Vargovich, M.S.
Opioid analgesics have been shown to be effective for short-term pain reduction; however,
chronic opioid therapy does not improve functioning, and may lead to problems with dependence
and abuse. Physicians report having difficulty discerning substance abuse or drug diversion,
which can lead to over- or under- prescribing, poor pain management, and may contribute to the
growing number of opioid-related overdose deaths. The primary aim of this study was to
determine if a psychological opioid risk evaluation influenced opioid prescribing in physicians at
the West Virginia University (WVU) Family Medicine Clinic. For this retrospective study,
participants were 151 (89 female) adult patients being considered for long-term opioid therapy.
Patients participated in a psychological opioid risk evaluation, which included several
questionnaires and a clinical interview. This evaluation resulted in an opioid risk level (i.e., low,
low-moderate, moderate, moderate-high, high) being assigned to each patient representing
clinical judgment about their potential risk for misusing or abusing opioid medication. An
electronic medical record review was conducted on each patient, abstracting information about if
an opioid was prescribed, in addition to several other factors, which later were included in
logistic regression analyses. Patients prescribed an opioid were more likely to be married or with
a long term partner and have a higher level of education. Patients not prescribed an opioid were
more likely to report a higher pain rating at the time of the evaluation, a history of abuse or
substance abuse, or have higher total scores for questionnaires measuring pain catastrophizing,
misuse or diversion behaviors, and depression symptoms. Risk status and substance abuse
history significantly predicted opioid prescribing, with a decrease in risk status resulting in an
increase in opioid prescribing, and those with a history of substance abuse being less likely to be
prescribed an opioid; however, substance abuse did not significantly improve the overall model
and was removed. Additionally, demographic variables (i.e., age, sex, ethnicity/race) were not
significant predictors of prescribing as found in other studies. These findings suggest that
providing physicians with additional information about their patient’s opioid abuse potential aids
in prescribing decisions and may reduce prescribing bias based on demographic factors. Risk
status may allow physicians to integrate evidence-based factors into their decision-making
process in a simplified manner, and possibly improve patient care. Future work should continue
to address physicians’ prescribing perspective, accuracy of evaluations, effect on patient care,
and cost analyses for the healthcare system.
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Predicting Opioid Prescribing Behaviors:
Influence of an Expert Opioid-Risk Evaluation
Treatments for chronic pain include a variety of pharmacological and nonpharmacological options, with opioid analgesics being a common treatment option (Turk et al.,
2011). The evidence for opioid analgesics supports short-term usage; however, long-term opioid
therapy has mixed results with some research indicating minimal pain reduction, and little to no
evidence for improvement in functioning (Furlan et al., 2006). Other treatments that are
effective in alleviating chronic pain include pharmacological, rehabilitative, medical, and
psychological treatment options, with surgical options being a less effective solution (Turk et al.,
2011). While opioid analgesics commonly are used in the treatment of chronic pain, there has
been an increase in misuse and abuse, as well as opioid-related overdose deaths across the United
States (Substance Abuse and Mental Health Services Administration, 2007; Warner et al., 2009).
Physicians are in a difficult position attempting to provide chronic pain patients with the best
possible care, while assessing patients for potential substance abuse and other issues.
Additionally, physicians report feeling unprepared to assess for substance abuse issues and
express concern over potential litigation for inappropriate prescribing of opioids (Matthias et al.,
2010; Richeimer, 2005). With chronic pain becoming one of the most common reasons patients
present for care (Cherry, Burt, & Woodell, 2003), it is essential for physicians to understand the
nature and treatment of this condition.
Conceptualization of Chronic Pain
Chronic pain is defined as “pain which has persisted beyond normal tissue healing time,”
which typically requires persistence of at least three months (International Association for the
Study of Pain, 1986). This definition does not account for the quality, type, and severity of such

PREDICTING OPIOID PRESCRIBING BEHAVIOR

2

pain, which limits its utility, both clinically and in research. Purves et al., (1998) proposed a
more comprehensive description, suggesting chronic pain be defined as “current continuous or
intermittent pain or discomfort which has persisted for more than three months, with recent or
frequent seeking of treatment or use of analgesic medication.” While this definition is not
without flaws, it provides greater differentiation between those with acute and chronic pain. By
identifying patients with chronic pain, health care professionals are better able to make treatment
decisions and assess patients’ progress over time.
Chronic pain is the most common reason patients seek medical services (Cherry, Burt, &
Woodell, 2003); however, estimates of prevalence vary greatly from study to study, with rates as
low as 7.6% and as high as 45%, with a median of 15% (Bowsher, Rigge, & Sopp, 1991;
Brattberg, Thorslund, & Wikman, 1989; Croft, Rigby, Boswell, Schollum, & Sillman, 1993;
Crook & Browne, 1984; James, Large, Bushnell, & Wells, 1991; Smith, Read, Grimshaw, Watt,
& Chambers, 1996; Von Korff, Dworkin, & Le Resche, 1990; Verhaak, Kerssens, Dekker, Sorbi,
& Bensing, 1998). Hardt, Jacobsen, Goldberg, Nickel, and Buchwald (2008) examined data
from 10,291 respondents to the National Health and Nutrition Examination Survey, finding
chronic pain estimates were 10.1% for back pain, 7.1% for pain in the legs/feet, 4.1% for pain in
the arms/hands, and 3.5% for headache. Chronic regional pain accounted for 11.0% of the
sample and chronic widespread pain, 3.6%. As found in other studies (Bassols, Bosch,
Campillo, Canellas, & Banos, 1999; Bowser et al., 1991; James, Large, Bushnell, & Wells, 1991;
Von Korff, Dworkin, Le Resche, & Kruger, 1988), women had higher rates than men for
headache, abdominal pain, and chronic widespread pain. While up to 45% of the population may
suffer from chronic pain, health services utilization suggests that between 10-15% of the
population suffers from clinical chronic pain (i.e., chronic pain that has been diagnosed
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clinically; Smith, Hopton, & Chambers, 1999). Thus, the majority of individuals reporting issues
with chronic pain may not be seeking medical services.
Chronic pain patients who are seeking health care services are managed through
specialist pain clinics, medical specialties (e.g., orthopedics), and a vast majority through
primary care (Clinical Standards Advisory Group; Crombie & Davies, 1998; Sullivan, Turner, &
Romano, 1991). One study mailed a survey to primary care providers in eight community clinics
and found that 37.5% of adult appointments in a typical week involved patients with chronic pain
complaints (Upshur, Luckmann, & Savageau, 2006). Twenty percent of chronic pain patients
presenting to primary care have pain due to malignancy; however, of the non-malignant chronic
pain patients approximately 50% have limb and joint pain and approximately 33% present with
back pain (Bowsher et al., 1991; Brattberg et al., 1989; Smith, Hopton, & Chambers, 1999).
Treatment of chronic pain often is complicated by multiple factors that contribute to the clinical
presentation. General physical health and psychological (e.g., depression) and psychosocial
factors are associated with chronic pain symptoms (Arnow et al., 2009; Bair, Wu, Damush,
Sutherland, Kroenke, 2008; Haley, Turner, & Romano, 1985; McCracken, Gross, Aikens, &
Carnrike, 1996; Spitzer, LeBlanc, & Debuis, 1987). Because of these multiple contributors,
there are several different treatment options that have demonstrated effectiveness in alleviating
chronic pain, including pharmacological, medical, psychological, and other interventions. For
further information on non-opioid treatments for chronic pain see Appendix A.
Opioid Treatment for Chronic Pain
Opioids are pain relieving medications, which bind to opioid receptors found in the brain,
spinal cord, gastrointestinal tract, and other organs in the body (National Institute on Drug
Abuse, 2011). After binding, they act to reduce the perception of pain, decrease the reaction to
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pain, and increase pain tolerance (National Institute on Drug Abuse, 2011). Furlan, Sandoval,
Mailis-Gagnon, and Tunks (2006) evaluated 41 randomized controlled trials in a meta-analysis
to determine the effectiveness of opioids for the treatment of various chronic pain conditions,
including osteoarthritis, diabetic neuropathy, low-back pain, and rheumatoid arthritis. The
authors concluded that opioids are capable of small reductions in pain severity and functional
improvement as compared to placebo; however, when compared to other analgesic medications,
they have similar reduction in pain, but less improvement in function. Trescot and colleagues
(2008) found weak evidence for the use of morphine and transdermal fentanyl for long-term
opioid therapy of six months or longer in managing chronic non-cancer pain; however, they
concluded there was limited evidence for all other controlled substances, including the most
commonly used drugs, oxycodone and hydrocodone. Therefore, there was not enough evidence
to determine that other controlled substances should or should not be used for long-term opioid
therapy. Two other systematic reviews concluded that due to the paucity of research on the
effectiveness of long-term opioid therapy, opioids should be used infrequently and when
prescribed only should be used for short-term pain relief (Manchikanti, 2004; Neush, Rutjes,
Husni, Welch, & Juni, 2009). Guidelines from two major pain associations (i.e., Neuropathic
Pain Special Interest Group of the International Association for the Study of Pain; European
Federation of Neurological Societies Task Force) recommend that opioids be reserved for the
second- or third-line of treatment in pain problems, but can be utilized as a first-line treatment
for episodic exacerbation of severe neuropathic pain (Attal et al., 2010; Dworkin et al., 2010).
While the long-term use of opioids is not supported by the current literature on chronic pain,
opioids remain the most potent analgesics available, and continue to be utilized for pain
management (Furlan et al., 2006).

4

PREDICTING OPIOID PRESCRIBING BEHAVIOR

5

Prevalence of Prescription Opioid Abuse in the U.S.
In recent years, the overall utilization of pharmaceuticals in the United States has greatly
increased with the average of all states up to 11.5 annual prescriptions per capita (IMS Health,
2012). This general increase includes controlled substances which have averaged a 7% increase
from 2010 to 2011. A growing public health concern is the abuse, dependence, and misuse of
prescription pain relievers in the United States. The National Survey on Drug Use and Health
(2007) reported that 12.5 million Americans used prescription pain relievers for nonmedical
purposes, an increase of 1.5 million from 2002. Approximately 70.2% of individuals who abuse
prescription opioids obtain the pills from friends or relatives by stealing, buying, or getting the
medication for free. Of these recreational users, 81.7% indicated that the opioids originated with
a prescription (Substance Abuse and Mental Health Services Administration, 2008).
Surprisingly, based on a 2009 survey of teenagers’ access to substances, prescription drugs
reportedly are easier to obtain than beer (The National Center on Addiction and Substance Abuse
at Columbia University, 2009). In addition to the increase in opioid misuse, the number of
patients admitted to substance abuse treatment facilities for nonheroin opiates and opioid abuse
increased four-fold from 23,000 to more than 90,000 from 1999 to 2007 (Substance Abuse and
Mental Health Services Administration, 2007). With significant increases in opioid prescriptions
and opioid misuse, there also has been a rise in prescription opioid overdoses. The Centers for
Disease Control and Prevention reported that 4,000 people died from opioid overdoses in 1999.
This number has more than tripled with nearly 15,000 people dying from opioid overdoses in
2008 (Warner, Chen, & Makuc, 2009).
Opioid misuse is a common problem across the United States, with special concern in
West Virginia. In a state by state comparison conducted in 2011, WV ranks eighth in overall
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prescription of controlled substances, with Monongalia county ranking among the highest
counties in WV (IMS Health, 2012). After dissecting opioid prescribing by specialty in WV,
family medicine ranked the highest with approximately 1,000 prescriptions in 2011 with the
second highest being internal medicine at approximately 600 prescriptions (IMS Health, 2012).
The Centers for Disease Control and Prevention reported that WV was ranked second in the U.S.
for overall opioid drug overdose deaths after examining data from 1999-2008 (Center for
Disease Control and Prevention, 2011b). These statistics indicate that opioid misuse is an
increasing problem across WV and the United States.
Cost of pain. When calculating the cost of pain to society, micro factors have to be
extrapolated to the macro level. Understanding the required medical treatment, complications
for other health problems, and decreased worker productivity is necessary to estimate the
national costs. Gaskin and Richards (2012) utilized the 2008 Medical Expenditure Panel Survey
to estimate cost of pain in the United States. Pain problems included both acute and chronic pain
issues. The authors found that pain costs range from $560 to $635 billion which is larger than
the annual costs of heart disease ($309 billion), cancer ($243 billion), and diabetes ($188
billion). Interestingly, individuals with pain average an additional $261 to $300 each compared
to individuals without pain. These estimates included health care costs attributed to pain and
lower work productivity due to pain. Birnbaum and colleagues (2011) specified their research to
the costs associated with prescription opioid abuse finding estimates close to $55.7 billion in
2007, an increase of $2.3 billion from estimates a year earlier (Hansen, Oster, Edelsberg, Woody,
& Sullivan, 2011). This estimate consists of workplace costs accounting for $25.6 billion (46%),
health care costs for $25.0 billion (45%), and criminal justice costs for $5.1 billion (9%). With
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opioid prescribing and misuse continuing to rise, the cost of pain to society stands to increase as
well.
Influence of Policy on the Healthcare System and Opioid Prescribing
In an attempt to slow the growth of opioid abuse, 34 states have initiated prescription
drug monitoring programs to identify drug abuse and diversion (Drug Enforcement
Administration Office of Diversion Control, 2011). Diversion includes using prescriptions for
recreational purposes, sharing or selling prescriptions with family members or friends, and any
other use not intended when prescribed (Gilson, Ryan, Joranson, & Dahl, 2004). In 2011, the
White House Office of National Drug Control Policy released a Prescription Drug Abuse
Prevention Plan focusing on education, monitoring, proper disposal, and enforcement to reduce
prescription drug abuse. First, education is aimed at increasing awareness about the dangers of
prescription drug abuse and information about how to properly dispense, store, and dispose of
controlled substance medications. Second, increased monitoring includes the use of prescription
drug monitoring programs and requiring patients to obtain controlled substances from one
provider. Third, developing and implementing consumer-friendly and environmentallyresponsible disposal programs aims to decrease “left-over” opioids from being misused. Lastly,
providing law enforcement agencies with the means necessary to prevent physicians from
overprescribing and stop drug seeking patients from “doctor shopping” (White House
Prescription Drug Abuse Prevention Plan, 2011). These nationwide changes are meant to
decrease opioid drug abuse and reduce overdose deaths.
As of July 2012, WV practitioners are required to conduct an initial search of the “West
Virginia Controlled Substances Monitoring Program database for information regarding specific
patients for whom they are providing pain-relieving controlled substances as part of a course of
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treatment for chronic, nonmalignant pain but who are not suffering from a terminal illness”
(West Virginia Code, 2012). The information obtained from this search must be documented in
the patient’s medical record. Additionally, the mandate requires annual checks for these patients,
with continued monitoring and documentation. Additionally, the Food and Drug Administration
recently has required opioid manufacturers to develop a Risk Evaluation and Mitigation Strategy
to manage potentially risky prescription drugs and ensure that the benefits of such drugs
outweigh the risks (Food and Drug Administration Department of Health and Human Services,
2008). By establishing these policies, the transaction costs for the patient increase. Transaction
costs are applied to economic models and the healthcare system referring to buying and selling,
but also to interpersonal and system interactions (Coase, 1937; Rice, 1998; Stiles, Mick, & Wise,
2001). More specifically, the frequency, specificity, uncertainty, limited rationality, and
opportunistic behavior associated with various interactions. In this situation, the transaction costs
refers to the increase in barriers (i.e., “costs”) to obtaining opioids by the patient and prescribing
these medications long-term for the physician. By increasing the transaction costs for patients, it
may result in a decrease in patients that misuse or abuse opioids presenting to clinics with more
regulations and guidelines as it would be too difficult to obtain a prescription. The purpose of
these mandates is to decrease opioid abuse, lessen the costs on the health care system, and
decrease inappropriate prescribing of opioids; however, it may lead to indirect harm of patients.
With greater attention on decreasing opioid misuse, legislation and policy may act to
increase physicians’ fear of prescribing opioids (i.e., opiophobia) and inadvertently punish
patients who are using their medications appropriately. Opiophobia is described as the fear that
appropriate opioid use will lead patients to become addicted to the medication, which results in a
failure to prescribe opioids due to the overestimation of risks, and therefore potentially under-
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treating a patient’s pain (Bennett & Carr, 2002; Morgan, 1985; Nathan, 2008). Physicians are
asked to determine if patients are malingering about their pain, a question, which many
physicians have reported, they are not adequately trained to assess (Richeimer, 2005). As a
result, they may avoid prescribing opioids in order to circumvent potential litigation. Medication
issues (e.g., inappropriate prescribing, over-prescribing, under-prescribing) are listed as one of
the top ten reasons why physicians are sued (Nathan, 2008). With the addition of stringent
policy, the possibility for litigation increases and many physicians may feel the potential risks of
prescribing opioids outweigh the benefits. Physician opiophobia may decrease inappropriate
opioid prescribing at the cost of harming the patients who are using opioids appropriately and are
benefiting from the medication.
Furthermore, the relationship between physicians and chronic pain patients can be
conflictual and complicated. Physicians may feel pressured to treat the pain with opioids, have
difficulty evaluating the veracity of the patients’ reports of pain, and worry about diversion of
opioids and misuse or abuse (Matthias et al., 2010). Additionally, because of the chronic and
complicated nature of chronic pain, physicians report feeling frustrated, overwhelmed, and/or
ungratified, when discussing care for patients with chronic pain (Matthias et al., 2010).
Alternatively, chronic pain patients report a strong desire to be believed by their physician, citing
a label or diagnosis as a confirmation of their chronic pain experience (Clarke & Iphofen, 2005).
Thus, with physicians required to question the veracity of a patient’s pain report and the patient
seeking confirmation of their pain experience, conflictual encounters are likely to occur. As a
result of the complicated and conflictual relationship, clinical care is negatively affected with
patients on chronic opioid therapy having a significantly lower incidence of receiving preventive
services, specifically cervical and colorectal cancer screenings (Buckley, Calvert, Lapidus, &
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Morris, 2010). Caring for patients with chronic pain on chronic opioid therapy is timeconsuming. Due to the high rate of opioid misuse, physicians often approach these patients with
a more critical perspective and are required to question the patient’s medication behaviors to
ensure appropriate usage (Bendtsen, Hensing, Ebeling, & Schedin, 1999; Bertakis, Azari, &
Callahan, 2003). This type of patient-clinician relationship may contribute to the increased
likelihood of those on chronic opioid therapy discontinuing care at a clinic, initiated by either
themselves or the clinic (Buckley et al., 2010). By requiring physicians to further question
patients on chronic opioid therapy and approach patients with distrust, the patient-clinician
relationship endures more strain and potential for conflict.
Need for Evaluations to Determine Appropriateness
A potential means to ameliorate the conflictual relationship between physicians and
patients on chronic opioid therapy is by engaging other professionals in the health care team
(e.g., psychologist, social worker). A pain consultant has the ability to provide an expert
assessment of the patient’s type, quality, intensity, and severity of pain as well as providing
treatment recommendations tailored to the patient’s pain problem. Additionally, a pain
consultant and their evaluation can provide the physician with a means to raise concerns and
discuss difficult topics about the patient’s treatment and behavior without damaging the
relationship. This approach allows the physician to maintain rapport with a patient and continue
to provide care in a potentially difficult situation by referring to a third party source of
information (i.e., pain consultant), rather than having the patient place blame on the physician
which may lead to feelings of distrust and resentment. Furthermore, the use of an opioid-risk
evaluation provides physicians with potential risk and protective factors to consider prior to
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prescribing an opioid, easing the decision making process and offering potential protection
against litigation.
Factors related to potential opioid misuse. Research on patient characteristics associated
with opioid misuse suggests there are several factors that are important to consider prior to
prescribing. The American Pain Society and American Academy of Pain Medicine released
Clinical Guidelines in 2009 for the use of chronic opioid therapy in patients with chronic noncancer pain. It was recommended that patient history, physical examination, assessment of the
patient’s family history, psychosocial factors, personal and familial history of substance abuse,
patient age, and psychiatric comorbidities be evaluated prior to prescribing chronic opioid
therapy (Chou, 2009).
Pergolizzi and colleagues (2012) support these criteria and recommend continued
monitoring and assessment of these characteristics over the course of treatment as well as
monitoring of aberrant drug taking behaviors. Continued monitoring and assessment is
recommended because of the dynamic nature of the criteria (e.g., emergence of mental health
condition, unemployment, divorce), thus the potential for risk status to change overtime.
Aberrant drug taking behaviors have been placed in four general categories: prescription requests
(e.g., early refill requests, lost pills, visits to the emergency room to obtain opioids), use of
medication for non-prescribed purposes (e.g., illicit drug use, using opioids to treat anxiety or
depression symptoms), illegal behaviors (e.g., stealing drugs, selling prescription drugs), and
other signs or behaviors (e.g., multiple dose escalations without prior authorization, concurrent
use of alcohol, hoarding drugs; Pergolizzi, 2012). All of these criteria have been found to be
potential signs of current or future opioid misuse among chronic pain patients (Breitbart et al.,
1997; Passik, Messina, Golsorkhi, & Xie, 2010; Portenoy, 1996; Turk, Swanson, & Gatchel,
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2008; Weaver & Schnoll, 2002; Ziegler, 2005). Physicians are encouraged to utilize drugscreening tests and patient self-report to assess for aberrant behaviors; however, patients who are
misusing medication are not likely to report this information to the physician. Additionally, all
clinicians treating chronic pain patients with opioids should recognize that all patients are at
some degree of risk because of the evidence that simply taking opioids is a risk factor for misuse
and abuse (Edlund, Sullivan, Steffick, Harris, & Wells, 2007; Jamison, Kaufmann, & Katz,
2000). Rice and colleagues (2012) proposed a model to identify patients at risk for prescription
opioid abuse, dependence, and misuse. They found that the following characteristics were most
predictive of abuse: male gender, prior opioid prescriptions, at least one prior prescription of
buprenorphine or methadone, at least one diagnosis of non-opioid drug abuse, mental illness,
hepatitis, or having a family member diagnosed with opioid abuse. While the assessment and
monitoring of risk factors is an important consideration when treating chronic pain patients on
long-term opioid therapy, it does not have to prevent the prescription of opioids. Research
suggests that even patients with an active opioid addiction may be successfully treated with
opioids; however, it requires closely monitored conditions, which may require more care than a
physician is able to provide (Weaver & Schnoll, 2002).
Medication Prescribing Decisions and Behaviors
The research examining prescribing behaviors and decision-making has focused on
factors that influence physician’s decision making process, how patient characteristics (e.g., race,
ethnicity) may influence prescribing, and physician characteristics and training. Nair,
Manchanda, and Bhatia (2010) found that physician prescribing behavior is significantly
influenced by the behavior of research-active specialists in the physician’s reference group.
Therefore, physicians are more likely to model their prescribing behavior after a respected
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specialist that is known to them. In a study examining physicians’ opioid knowledge, beliefs,
attitudes and prescribing practices, the authors found that physicians held many misconceptions
about the prescribing of opioids (e.g., appropriateness of prescribing opioids for chronic pain,
characteristics of addiction) and reported that fear of investigation led them to lower the dose
prescribed, limit the number of refills, or prescribe a Schedule III or IV rather than a Schedule II
opioid (Wolfert, Gilson, Dahl, & Cleary, 2010). This information suggests that physicians may
be more likely to modify their prescribing behaviors out of fear of legal recourse rather than
based on patient characteristics.
Additionally, studies have shown that ethnic and racial minorities are less likely to be
prescribed opioid analgesics than white patients (Olsen, Daumit, & Ford, 2006; Pletcher,
Kertesz, Kohn, & Gonzales, 2008; Tamayo-Sarver, Hinze, Cydulka, & Baker, 2003). Burgess
and colleagues (2008) expanded upon this research by examining race combined with patients
exhibiting challenging and non-challenging behaviors, with challenging behaviors being
described as the patient being aggressive about his need for stronger pain medication, asking for
drugs by name, reporting that he tried his wife’s prescription for Percocet, and being highly
expressive about his pain and his need for relief. The authors found that physicians were more
likely to prescribe a higher dose or a stronger opioid for black patients exhibiting challenging
behaviors than non-challenging behaviors. Interestingly, the result was opposite for the white
patients, with physicians more likely to prescribe higher doses or a stronger opioid for nonchallenging patients. Another study showed that male physicians prescribed more opioids to
white patients, while female physicians prescribed more opioids to black patients (Weisse,
Sorum, Sanders, & Syat, 2001). Lastly, Hirsh, George, and Robinson (2009) demonstrated that
sex, race, age, and pain expression cues accounted for significant variance in decision making
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among nurses prescribing opioids in a virtual human model. In this study, females, African
Americans, older patients, and patients expressing high pain via facial expressions were more
likely to be prescribed an opioid.
Several physician and practice characteristics also influence opioid prescribing, including
age, knowledge about treating pain, and beliefs and attitudes about opioids. Younger age seems
to be associated with more “liberal” views on prescribing opioids (e.g., favor earlier intervention
for pain control, more patient control over analgesics); however, this study examined prescribing
in chronic cancer pain (Cleeland, Cleeland, Dar, & Rinehardt, 1986). This result later was
found in prescribing for non-cancer chronic pain, with younger age being associated with
prescribing opioids (Hutchinson, Moreland, de Williams, Weinman, & Horne, 2007). Another
study found that previous experiences with patients addicted to drugs significantly influenced
opioid prescribing, with physicians being less likely to prescribe opioids for fear of contributing
to abuse or dependence (Dobscha, Corson, Flores, Tansill, & Gerrity, 2008). Additionally,
physicians unwilling to prescribe opioids held stronger beliefs that prescribing would lead to
patient abuse, addiction, and potential legal recourse (Nwokeji, Rascati, Brown, & Eisenberg,
2007). Glajchen (2001) reviewed barriers to treating chronic pain finding that lack of knowledge
about opioids, negative attitudes toward prescribing opioids, and inadequate pain-assessment
skills resulted in decreased opioid prescribing and poor pain management. Two other studies
corroborated these conclusions finding physicians were dissatisfied with their training on pain
(Hutchinson et al., 2007) and opioid prescribing was determined by personal beliefs about
opioids, with those with at least a moderate belief in the effectiveness of opioids being more
likely to prescribe (Hutchinson et al., 2007; Nwokeji et al., 2007). Physician misconceptions and
inadequate pain management training, fear of legal recourse, lack of knowledge about laws and
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regulations, and certain patient characteristics may result in decreased opioid prescribing and
inadequate management of pain.
Research addressing the complex problem of opioid misuse and opioid prescribing
behaviors and their implications on societal costs and health care policy is important and has the
potential to be quite impactful. The long-term goal of the current project is to improve our
understanding of opioid prescribing decisions made by physicians and to use that information to
inform prescriber education and health care policy. Understanding the interplay of chronic pain,
opioid misuse, and opioid prescribing is critical for clinicians and researchers addressing this
public health problem. This project provides a more thorough conceptualization of influences on
opioid prescribing decisions, and an understanding of how to better avoid opioid misuse in
chronic pain patients and how best to communicate potential risk and need to physicians.
Statement of the Problem
More thorough investigation of opioid prescribing behaviors could prove important for a
numbers of reasons. First, prescription overdose deaths have seen a dramatic increase over the
past 15 years, eclipsing both cocaine and heroin overdose deaths (Center for Disease Control and
Prevention, 2011a). This increase is in part due to misguided views of prescription medication
as being “safe” by the public; however, as overdose deaths have increased so have the number of
prescriptions written by physicians (Center for Disease Control and Prevention, 2011c). With
the high stress associated with patient care, physicians may not have the time or resources to
adequately assess patients prior to prescribing (Matthias, 2010). As a result, physicians may
under- or over-prescribe opioid analgesics resulting in inadequate management of pain. With an
increased understanding of opioid prescribing decisions, overprescribing or incorrect prescribing,
which can lead to overdose deaths, could potentially be reduced. Thereby, improving patient
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care and providing individuals with the most appropriate treatment interventions for their
specific condition.
Second, physicians often lack training in discerning substance abuse or drug diversion
(i.e., the use of prescription drugs for recreational or non-prescribed purposes) in patients and
report feeling unprepared to coordinate care for patients with substance abuse and/or other
psychological problems (Glajchen, 2001; Richeimer, 2005). A logical solution seems to be to
provide physicians with an expert pain psychologist’s assessment of the patient’s potential for
use and misuse; however, this solution has not been evaluated in the literature. If successful, an
expert opioid-risk evaluation may alleviate some of the strain on the physician-patient
relationship by improving physician knowledge of their individual patient. Additionally, when a
patient needs to be denied opioid analgesics for chronic pain, the physician can utilize the
consultant’s evaluation as a means to avoid blame, and attempt to maintain the patient-physician
relationship, while providing alternative treatments.
Third, better understanding of how specific variables influence opioid prescribing in
regard to opioids, especially an expert opioid-risk evaluation, will inform the protocol for
prescribing controlled substances and have implications for larger health care policies. Factors
that significantly influence physician prescribing of opioids could be targets of efforts to reform
policy, such as including more psychologists in the medical setting and increasing coverage of
mental health evaluations and interventions by insurance companies.
Previous research has demonstrated that physician qualities (e.g., beliefs about opioids
for treating chronic pain) and patient characteristics (e.g., ethnicity/race) influence prescribing
behaviors (Glajchen, 2001; Hutchinson et al., 2007; Nwokeji et al., 2007; Olsen et al., 2006;
Pletcher et al., 2008; Tamayo-Sarver, 2003; Wolfert et al., 2010). Moreover, it seems to be
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affected by “opinion leaders” or specialists in the physician’s reference group, with physicians
being more likely to imitate the prescribing behavior of specialist physicians (Nair et al., 2010).
Knowing that physicians are more likely to follow the opinion of a specialist physician suggests
that they may modify their prescribing behavior when presented with a psychologist’s expert
assessment; however, this scenario has not been addressed in the literature. Additionally, there is
a limited literature addressing how factors outside of the physician influence opioid prescribing
behaviors and how patient factors guide physicians’ script writing. Establishing these
associations is a critical step in understanding the complex nature of physician prescribing
behavior and will afford a more thorough understanding of potential means to decrease
overprescribing and improve patient care.
The effect of opioid prescribing decisions on patients and the larger issue of public health
substantiate the importance of further examination. Although there is research that has examined
physician characteristics that influence prescribing, there are few studies that explicitly target
opioid prescribing and factors outside of the physician. Consequently, a crucial need in this area
is the investigation of opioid prescribing behaviors. The present study is designed to determine if
the results of an independent opioid risk evaluation influence prescribing decisions and to further
explore other variables, outside of the physician, that may impact prescribing decisions.
Research Questions
The current study was largely exploratory in nature as there has not been an examination
of the influence of an opioid risk evaluation on opioid prescribing behavior. As such, a priori
hypotheses are not appropriate. The current investigation of the influence of opioid risk-status
and patient characteristics on opioid prescribing behavior had four major research questions:
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1. Were patients who were prescribed opioids at the first appointment following the opioid
risk evaluation different from those who were not prescribed an opioid? The groups may
differ on the self-report measures, with the former group having lower scores than the
latter on the Pain Catastrophizing Scale, Screener and Opioid Assessment for Patients
with Pain-Revised, Pain Disability Index and Beck Depression Inventory-II.
Additionally, patients may differ on demographic variables, such as level of education.
2. Did the patient’s opioid risk status affect whether a physician prescribed an opioid at the
first appointment following the evaluation? Each patient was ascribed a risk level (i.e.,
low, low-moderate, moderate, moderate-high, or high risk) following the risk evaluation.
The physician may use this information when prescribing an opioid, and potentially,
those ascribed a higher risk category are less likely to be prescribed an opioid.
3. What other variables influenced physician opioid prescribing behavior? Based on the
literature, history of substance abuse, family history of substance abuse, cigarette
smoking, mental illness, and being male are associated with opioid misuse. Examination
of these variables as they relate to predicting physician prescribing behavior may provide
valuable information.
4. How did the inclusion of opioid risk status and other significant variables (as determined
in research question three) affect whether a physician prescribed an opioid at the first
appointment following the opioid risk evaluation? Analyses resulted in a comprehensive
model of variables predicting physician prescribing behaviors.
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Methods
Study Design
Between October, 2010 and March, 2013 chronic pain patients requesting or being
considered for opioid pain medication presenting to the West Virginia University Department of
Family Medicine clinic were referred to the Family Medicine psychology team for an opioid risk
evaluation. Attending physicians are expected to refer patients for opioid risk evaluations, while
resident physicians are required to refer their patients upon presentation for chronic opioid
therapy. The patients had a chronic pain condition diagnosed by their primary care physician
prior to the evaluation; however, the duration of the chronic pain varies across patients, all
meeting the minimum requirement of lasting longer than three to six months. These patients
were asked to participate in a clinical interview and to complete a number of self-report
measures (described below) to assess for potential psychopathology, current functioning with
pain, and potential for opioid abuse or misuse. The present study, utilizing a retrospective cohort
design, followed up on the outcome of those opioid risk evaluations by way of electronic medical
record review. Opioid risk status, whether or not the patient was prescribed an opioid, various
demographic factors, and pain condition were abstracted from electronic medical records for
each patient. Physician’s decision to prescribe or not prescribe an opioid analgesic was
compared across patients with varying levels of opioid risk status and a predictive model was
developed to better explain the factors which may be influencing a physician’s decision to
prescribe.
Participants
Participants were adult (age ≥ 18 years at the time of the evaluation) patients who
reported to the West Virginia University Department of Family Medicine clinic for an opioid risk
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evaluation conducted by a psychologist or psychology trainee. The patients were referred to the
Family Medicine psychologists because he or she was being considered for opioid therapy for a
chronic pain condition. As outlined by the Family Medicine Clinic policy, prior to prescribing
long-term opioids, the resident physicians at the Family Medicine clinic are required to refer
patients for an opioid risk evaluation and the attending physicians are expected to refer patients.
(See Appendix B for additional information on the Family Medicine procedure). These
evaluations were conducted by one of the following individuals: faculty/licensed psychologist,
postdoctoral psychologist, predoctoral intern, clinical or counseling psychology graduate student.
All unlicensed psychologists, interns, or graduate students were supervised by a licensed
psychologist who directly observed either in the room or via a video camera viewing system. At
the time of the patient’s visit, he or she completed a number of self-report instruments related to
pain quality, intensity, and duration, functioning affected by pain, negative cognitions about
pain, fear of activity and movement, risk for future misuse of opioids, current behaviors
indicating medication misuse, and mood, in addition to a short demographic questionnaire. The
patients also participated in a clinical interview conducted by a psychologist or trainee to better
understand his/her pain triggers, goals for pain and function, impact of pain on functioning, pain
treatment history, social and family history, and personal and familial substance abuse history.
Initially, electronic record reviews were conducted on 158 patients; however, seven cases
were excluded due to having two opioid risk evaluations in their record; therefore the evaluation
that took place at a later date was removed and the first evaluation chronologically was utilized
in the study. Opioid risk evaluations included in this sample totaled 151 (59% female) patients.
Based on guidelines established by Hosmer and Lemeshow (2000), a minimum number of 10
cases per independent variable are recommended for conducting a logistic regression, with a
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preferred case-to-variable ratio of 20 to 1. By including 151 patients, the analyses can include
between 7-15 independent variables in the final predictive model. These patients were further
categorized based on their opioid risk status with 36 (23.8%) recorded as low risk, 14 (9.3%) as
low-moderate risk, 39 (25.8%) as moderate risk, 19 (12.6%) as moderate-high risk, and 43
(28.5%) as high risk. Due to unequal sample size in each category resulting in small cell sizes
for analyses, the low and low-moderate group was combined and the moderate and moderatehigh group was combined. These changes resulted in the following categories: 50 (33.1%)
recorded as low/low-moderate risk, 58 (38.4%) as moderate/moderate-high risk, and 43 (28.5%)
as high risk. See Tables 1 and 2 for information about referrals, risk status, and evaluations. Of
note, it may appear when examining Table 2 that there are differences in the assigned risk status
and the psychologist/trainee; however, these potential differences seem to be related to the
scheduling process and characteristics of the psychologist/trainee.
Generally speaking, participants of the project were residents of Morgantown and
surrounding areas of West Virginia and Pennsylvania and represent the ethnic and racial makeup of the Appalachian area. For this study, 96.7% of the sample reported their race/ethnicity as
“white/Caucasian” and 3.3% reported “black/African American.” The mean age of the sample
was 48.2 years (SD = 11.1), with patients ranging from 19 to 80 years old. The sample consisted
of 89 females (58.9%) and 62 males (41.1%). The education level of participants was as
follows: 11th grade and below (29, 19.2%), high school graduate or GED (65, 43.0%),
Associate’s degree or some college (30, 19.9%), and Bachelor’s degree or higher (17, 11.3%).
Opioid Risk Evaluation
Patients participating in the opioid risk evaluation typically were new chronic pain
patients attempting to establish care at the Family Medicine clinic; however, any individual
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attempting to or being considered for long term opioid treatment can be referred for an
evaluation. The resident physicians at the clinic are required by department policies to refer their
patients and the attending physicians are expected to refer their patients, but may not follow this
guideline unless they have a concern about the patient (e.g., psychological problem, substance
abuse). Additionally, patients presenting with obvious high risk indicators (e.g., active substance
abuse or opioid misuse) may not be referred for an opioid risk evaluation and instead may be
rejected for opioid consideration by the physician before beginning the evaluative process. As
previously described, the patient meets with a psychologist or psychology trainee for a clinical
interview which addresses his/her pain triggers, goals for pain and function, impact of pain on
functioning, pain treatment history, social and family history, and personal and familial
substance abuse history. After this interview, the trainee and supervisor thoroughly discuss the
case and identify any potential problem areas based on information in the literature. If a trainee
was not involved, the licensed psychologist identifies problem areas independently. These
potential problem areas include: history of substance abuse, family history of substance abuse,
psychopathology, alliance with provider, history of compliance, lifestyle stability, willingness to
pursue pain management options other than opioids, and mental health problems.
After discussing the patient, reviewing the patient’s medical record, and interpreting their
self-report measures, a risk status is ascribed to the patient. This risk status is based on the
number and severity of each potential problem area, which then is interpreted into one of the
following risk categories: low, low-moderate, moderate, moderate-high, or high, as previously
described. Certain factors may be weighted more heavily due to the abundance of research
regarding the risk of opioid abuse and said factor. For example, if a patient has an extensive
history of substance abuse with numerous failed sobriety attempts or no sobriety attempts, this
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patient likely would be considered high risk. Other factors that likely indicate high risk include
current substance abuse, and evidence of diversion or medication misuse/abuse.
Next, a report is generated which outlines the presenting problem, medical/psychological
history, current medications, history of pain problem, relevant psychosocial history, current
status and functioning, mental status, standardized testing (i.e., McGill Pain Questionnaire, Pain
Disability Index, Tampa Scale for Kinesiophobia, Beck Depression Inventory-II, Screener and
Opioid Assessment for Patients), diagnostic impressions, and lastly the conclusions and
recommendations. The conclusions and recommendations section outlines the patients risk
status for misuse of opioid pain medications, presents positive indicators and cautions, and
specific treatment options that may be helpful for the patient, which may or may not include a
recommendation for opioid analgesics. This report is included in the patient’s medical record
and is not considered a protected document as most psychiatry notes. The purpose is for this
information to be accessible to the physicians managing the patient’s pain problem. Because this
report is not protected beyond the strict standard of access to the medical record system, the
writer of the report will not include detailed information about potentially sensitive topics, such
as sexual abuse. Instead the writer may indicate that the patient experienced abuse, and report
more specific information directly to the physician, if it seems necessary for treatment. This
safeguard is in place to protect the patient’s privacy and maintain confidentiality.
Considering the prescribing of opioid analgesics, it is important to note that the West
Virginia University Department of Family Medicine has policies in place which have evolved
over the course of the past few years. The requirement of opioid risk evaluations prior to
prescribing was established in Fall 2010 and additional guidelines were added, including a check
of the Board of Pharmacy for the patient, urine drug screens prior to prescribing and periodically

PREDICTING OPIOID PRESCRIBING BEHAVIOR

24

thereafter, and an approximate 30 day waiting period before physicians are allowed to prescribed
analgesic narcotics to patients. Of note, no other study has been conducted in a setting with this
type of system-level protocol in place. Therefore, it is unclear how such a protocol may affect the
outcome of this investigation; however, its impact may be such that there is a decrease of high
risk patients continuing treatment in this setting due to the “transaction costs” (Coase, 1937;
Rice, 1998; Stiles, Mick, & Wise, 2001).
Self-Report Measures
Demographic and general pain information questionnaire. The demographic form is
a self-report questionnaire consisting of approximately 30 items (see Appendix C). It covers
general demographic information, queries the respondent about number of times the patient has
utilized the emergency department in the past year, tactics attempted to alleviate pain (e.g., yoga,
physical therapy, medication) and the patients perceived degree of helpfulness, as well as
caffeine, alcohol, nicotine, and other substance use. Additionally, it includes items related to
previous and current psychological symptoms (e.g., loss of energy, feeling nervous, hearing
voices in your head).
Short Form-McGill Pain Questionnaire. The Short Form-McGill Pain Questionnaire
(SF-MPQ) is a 15-item self-report questionnaire which utilizes a four-point scale (0 = none to 3
= severe) requiring respondents to indicate the severity of various pain descriptors (e.g.,
throbbing, gnawing, splitting; Melzack, 1987; see Appendix D). It consists of 11 sensory words
and 4 affective words. Patients also rate their present pain intensity on a 0–5 scale. Total score
ranges from 0-45; however, this measure may be best utilized to understand the type, intensity,
and affective nature of the pain as the total score does not provide quantitative cut-offs for
interpretation.
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Administration time for the SF-MPQ is short, the instrument is widely used, and there is
good evidence of reliability and validity. The SF-MPQ has good internal consistency reliability
(r = 0.73-0.89; Burckhardt & Bjelle, 1994) and demonstrates strong concurrent validity with the
MPQ total score (r = 0.67-0.87; Melzack, 1987). The SF-MPQ also has demonstrated an
appropriate level of overlap (r = .51 to .94) with other pain measurements (e.g., Long-Form
McGill Pain Questionnaire, Present Pain Intensity, Visual Analogue Scale; Melzack, 1987).
Test-retest reliability over one- to three-days apart ranged from 0.62 to 0.95 in samples of
patients with musculoskeletal pain and rheumatic pain (Strand, Ljunggren, Bogen, Ask, &
Johnsen, 2008). The SF-MPQ is a good measure of pain quality and intensity and has
demonstrated adequate reliability and validity for inclusion in the current study. Internal
consistency in this study was acceptable for the SF-MPQ (α = .84).
Pain Disability Index. The Pain Disability Index (PDI) is a 7-item, self-report measure
designed to assess the degree to which several aspects of the patient’s life presently are disrupted
by persistent pain (Pollard, 1984; see Appendix E). Respondents are asked to rate, on a 10-point
scale (0 = no disability to 10 = total disability), the level of disability they experience due to
persistent pain in various life activities (e.g., family and home responsibilities, recreational
activities). Total scores range from 0-70; higher scores indicate greater disability.
The PDI has the following strengths: short administration time, assessment of disability
level related to a broad range of life events, established norms for clinical (i.e., chronic pain)
populations, and well-evidenced reliability and validity. Internal consistency was good,
Cronbach’s α = .86, within a chronic low back pain sample (Pollard, 1984). Test-retest
reliability over a one week interval was found to be good, ICC = .91 (Grönblad et al., 1993; Tait,
Chibnall, & Krause, 1990). Additionally, Pollard (1984) found that using the PDI allowed
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differentiation between patients with chronic low back pain who were categorized as highly or
minimally disabled. For the demonstrated ability to discriminate between those with high and
low disability and the adequate reliability and validity, this instrument is of value for the present
study. Cronbach’s alpha for the PDI in the current study was .83.
Pain Catastrophizing Scale. The Pain Catastrophizing Scale (PCS) is a 13-item selfreport measure of thoughts and feelings patients may have when in pain (Sullivan, Bishop, &
Pivik, 1995; see Appendix F). Respondents rate the degree to which they experience various
thoughts and feelings on a five-point Likert-type scale from not at all to all the time. Examples
of items include “I worry all the time about whether the pain will end” and “There’s nothing I
can do to reduce the intensity of the pain.” The PCS yields a total score (0-52) and three
subscale scores assessing rumination, magnification and helplessness. Higher scores indicate
more negative thoughts and feelings about pain.
The PCS is relatively short, there are established norms for clinical (i.e., chronic pain)
and nonclinical populations, and there is good evidence of reliability and validity. The PCS has
adequate to excellent internal consistency for both the total score (Cronbach’s α = .87) and
subscales (rumination, α = .87; magnification, α = .66, and helplessness, α = .78; Sullivan et al.,
1995). Test-retest reliability over a six-week period was found to be good by Sullivan et al.,
(1995), r = 0.75. Studies by Osman et al., (1997 & 2000) found additional support for the threefactor structure of the PCS and further evidence of reliability, as well as criterion-related,
concurrent, and discriminant validity. For its ease of use and well-evidenced reliability and
validity, the PCS is a good measure of negative cognitions associated with chronic pain for the
current study. Internal consistency for the PCS in this study was acceptable (α = .94).
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Tampa Scale for Kinesiophobia. The Tampa Scale for Kinesiophobia (TSK) is a 17item, self-report measure designed to assess the degree to which patient’s fear or worry about
movement and activity (Miller, Kori, & Todd, 1991; see Appendix G). Respondents are asked to
rate, on a 4-point scale (1 = strongly disagree to 4 = strongly agree), the degree to which each
statement represents their feelings. Items include, “I’m afraid I might injure myself if I
exercise,” and “People aren’t taking my medical condition seriously enough.” Total scores range
from 17-68; higher scores indicate greater fear of movement or activity.
Administration time for the TSK is relatively short, there are established norms for
clinical (i.e., chronic pain) and nonclinical populations, and good evidence of reliability and
validity. In a sample of adults with chronic back and/or neck pain, a Cronbach’s alpha of 0.84
was observed, indicating a high level of internal consistency (French, France, Vigneau, French,
& Evans, 2007). Test-retest reliability of the total score has been established by SwinkelsMeewisse, Swinkels, Verbeek, Vlaeyen, and Oostendorp (2003), r = 0.78. Convergent and
discriminant validity was found to be good when compared to other measures of fear-avoidance
behavior and pain catastrophizing (French et al., 2007). Additionally French and colleagues
(2007) found additional support for the two-factor model originally found by Clark, Kori, and
Brockel (1996) and later reaffirmed by Roelofs, Goubert, Peters, Vlaeyen, and Crombez (2004).
For its ease of use and well-evidenced reliability and validity, the TSK is a good measure of fear
and avoidance of movement and activity for the current study. Cronbach’s alpha for the TSK in
the current investigation was .81.
Screener and Opioid Assessment for Patients with Pain-Revised. The Screener and
Opioid Assessment for Patients with Pain-Revised (SOAPP-R) is a 24-item self-report measure
utilized for screening risk potential for aberrant medication-related behavior among persons with
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chronic pain (Butler, Fernandez, Benoit, Budman, & Jamison, 2008; see Appendix H).
Respondents rate the frequency they experience symptoms and events related to opioid misuse
on a five-point Likert-type scale from never to very often. Examples of items include “How
often do you have mood swings” and “How often have you counted pain pills to see how many
are remaining.” Total score ranges from 0-96, scores ≥18 indicates the patient is at risk for
opioid misuse.
The SOAPP-R is widely used to assess potential for opioid abuse, there are established
norms for clinical (i.e., chronic pain) and nonclinical populations, and good evidence of
reliability and validity. In a sample of patients prescribed opioid medication for chronic
noncancer pain, a Cronbach’s alpha of 0.88 was observed, indicating adequate internal
consistency and excellent test-retest reliability over one week was demonstrated, r = .92 (Butler
et al., 2008). Convergent and discriminant validity was found to be good when compared to
other measures of aberrant drug behavior and social desirability (Butler et al., 2008). The
SOAPP-R provides important information about the potential for opioid misuse and
demonstrates good reliability and validity; as such it is a valuable measure for this investigation.
Internal consistency for the SOAPP-R in the current study was acceptable (α = .90).
Beck Depression Inventory-II. The Beck Depression Inventory-II (BDI-II) is a 21 item
self-report questionnaire which utilizes a four-point scale (0 = minimal to 3 = severe) requiring
respondents to indicate the severity of depressive symptoms (Beck, Steer, & Brown, 1996). The
items on the BDI-II include questions relating to hopelessness, irritability, guilt, fatigue, weight
loss, and lack of interest in sex. Total score ranges from 0 to 63, with cutoff scores indicating
minimal, mild, moderate, and severe depression.
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The BDI-II is widely used both clinically and in research, there are established norms for
clinical (i.e., chronic pain) and nonclinical populations, and good evidence of reliability and
validity. Both high internal consistency (α = .92) and high convergent validity have been
established for the BDI-II based on Pearson correlations between the BDI-II and the depression
scale of the SCL-90-R (r =.89; Steer, Clark, & Beck, 1999). Additionally, in a sample of chronic
pain patients, internal consistency remained high (α = .92), and results supported a singular
second-order latent construct with three-factor subscales (i.e., Negative Attitude, Performance
Difficulty, and Somatic Elements; Harris & D’Eon, 2008). Test-retest reliability over a oneweek period was found to be good by Sprinkle et al. (2002), r = 0.96, which is similar to that
found by Beck, Steer, and Brown (1996), r = .93. Because it has well-evidenced reliability and
validity for both chronic pain and nonclinical samples, the BDI-II is a good measure of
depression for the current study. Cronbach’s alpha for the BDI-II in this study was .91. The
BDI-II is not displayed in the appendices due to its copyrighted status.
Electronic Medical Record Review
Electronic medical records were available for all of the participants of the study through
the West Virginia University Department of Family Medicine clinic. Information gathered from
the electronic medical record was immediately entered into a database to assure complete
abstraction across participants. Several variables were collected including, whether the patient
was prescribed an opioid at the first appointment following the opioid risk evaluation, the
prescribing physician’s training level and sex, patient’s primary pain condition, mental health
diagnoses, history of substance abuse, family history of substance abuse, history of abuse,
employment status, smoking status, education level, evaluator training level, Board of Pharmacy
review, urine drug screen, as well as the patient’s sex, age, ethnicity/race, and scores on the
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SOAPP-R, PCS, PCI, TSK, and BDI-II. This chart review process provided a comprehensive
and standardized measure of potential factors related to being prescribed an opioid.
Access to electronic medical records was approved by the West Virginia University
Department of Family Medicine dean and the appropriate faculty and administrators. Electronic
medical record reviews were conducted by Alison Vargovich, under the supervision of
collaborators at the Department of Family Medicine. Chart abstraction reliability was assessed
via abstraction comparison for 10% of the cases across 158 participants with reliability checks
conducted every 20 participants by Jeannie Sperry, Ph.D., as she was the Family Medicine
supervisor at the time. Reliability was excellent across the data collection window; there were
no discrepancies in the recorded outcome variables, and minimal discrepancies in all other
variables collected across patients. More specifically, for all participants included in the
reliability checks, 240 out of 260 variable cases, or 90.2%, were congruent between the dataset
and reliability check. There were 26 out of 266 variable cases with discrepancies (9.8%), but
after closer inspection only 4 out of those 26 variable cases, or 15.4%, required a modification to
the dataset. Prior to data collection, Alison Vargovich and Jeannie Sperry, Ph.D. were trained on
the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy and Security
Rules and had current ethics training and Collaborative Institutional Training Initiative (CITI)
program certification for work with human subjects.
Results
All Statistical analyses were performed using PASW Statistics 21.0.0.0 (IBM SPSS,
Chicago, IL). Variables first were examined to ensure there were no out-of-range values that
were theoretically impossible based on the structure of the variable (e.g., possible questionnaire
responses), and any issues addressed.
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As suggested by Menard (2010), preliminary analysis of the data was performed to check
the assumptions of logistic regression with respect to the selected predictors of the study.
Univariate outliers were detected by considering histograms and box plots for each variable.
There were 18 individual data points detected as potential outliers across all of the variables.
These outliers were further evaluated by comparing the mean to the 5% trimmed mean to
determine the influence the potential outliers were having on the data (Pallant, 2010). These
outliers were not determined to be significantly influencing the mean and were included in the
dataset. Outliers for dichotomous variables were examined through frequencies to determine if
any violated the 90%-10% split between groups; no variables violated this guideline (Howell,
2010). Multivariate outliers were screened by checking the data for participant leverage values
greater than 2k/N, where k equals the number of predictor variables (Tabachnick & Fidell, 2007);
no variables violated the multivariate outlier guidelines.
All predictor variables were subjected to linear regression analysis to evaluate
multicollinearity (Menard, 2010). Multicollinearity among predictors in logistic regression
creates problems for the validity of the model for the investigation. In particular, it affects the
validity of the statistical tests of the regression coefficients by inflating their standard errors
(Garson, 2010). The results of the analysis showed the data did not violate the multicollinearity
assumption. The collinearity statistics, specifically tolerance values and the variance inflation
factor, were examined. None of the variables were below the recommended guideline of .10 for
tolerance or above 10 for the variance inflation factor, suggesting that there were no problems
with multicollinearity among the variables (Field, 2005; Pallant, 2010). See Table 3 for
collinearity statistics. Additionally, a bivariate correlational analysis was conducted to determine
high correlations among variables (≥ .80; Tabachnick & Fidell, 2007). The variables with the
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highest correlation were the total score for the SOAPP-R and BDI-II, r = .65, p < .001; and no
variables met or exceeded the suggested guideline. See Table 4 for bivariate correlations for
questionnaires.
To address missing data, multiple imputation (MI) was utilized in order to reduce errors,
maintain statistical power, and retain the cases in the dataset (Osborne, 2013). The MI statistical
technique has been demonstrated to be superior to mean substitution, listwise deletion, and single
imputation and results in greater generalizability and replicability as it explicitly models the
missingness and gives the researcher confidence intervals for estimates rather than trusting to a
single imputation (Schafer, 1999; Schafer & Graham, 2002). The MI method involves three
steps, imputation, analysis, and pooling. First, the missing entries of the incomplete dataset are
“filled in” or “imputed” with plausible values based on the distribution of the data derived from a
combination of Bayesian theory and Monte Carlo technique. These plausible values are imputed
into a designated number of datasets determined by the researcher. The suggested number is
between 5 and 20 (Schafer, 1999; Schafer & Graham, 2002), but for these analyses it was
determined that 10 imputed datasets would be sufficient due to the relatively small amount of
missing values. This first step results in 10 imputed datasets with plausible values replacing the
missing items. The second step, analysis, refers to the planned analyses that are conducted
utilizing all of the imputed datasets, which results in the final step, pooling. The output for the
analyses includes statistics based on each imputed dataset, which is then combined and analyzed
to provide “pooled” statistical output.
In order to utilize the MI method, it is assumed the missing data are random; however,
while it is preferred to be missing at random, the MI method is resilient to various types of
missingness (Little & Rubin, 2002). Additionally, to utilize the MI method effectively, it is
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important to understand the total percentage of missing items and the percentage missing within
a variable; however, the number missing within each case is irrelevant to the analyses as these
values can be imputed accurately providing there is sufficient data within the variable (Schafer,
1999; Schafer & Graham, 2002; Tabachnick & Fidell, 2012). Due to the rigorous nature of the
record review, there were minimal missing data in the variables collected from the patient’s
medical record (1.7%); however, there were missing data among the self-report measures, which
is what the multiple imputation was utilized to address. In the current study, missing data were
analyzed for patterns through the multiple imputation analyze patterns feature of SPSS to
determine missingness. There were no significant patterns identified and it was determined that
the missing values were missing at random. Further assessment of the missing values within the
self-report measures revealed 5.6% missing across all of the participants in the form of items on
the questionnaires. Additionally, there was <10% missing within each measure item, which is the
suggested guideline (Bennett, 2001); however, Tabachnick and Fidell (2012) indicated that the
missing data mechanisms and the missing data patterns likely have greater impact on research
results than the proportion of missing data. See Table 5 for the percentage of missing items for
each measure.
Primary Data Analyses
Research Question 1
Were patients who were prescribed opioids at the first appointment following the
opioid risk evaluation different from those who were not prescribed an opioid? Descriptive
statistics (e.g., means and standard deviations) for relevant dependent and independent variables,
across the entire study sample are reported in Tables 6 and 7. Additional information about
differences in demographic and psychosocial variables by opioid prescribing group is in Tables 8
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and 9. Chronic pain diagnoses and mental health problems across groups are presented in Table
10. Across groups (i.e., prescribed an opioid, not prescribed an opioid) patients did not differ
significantly in demographic variables, specifically age, t (149) = -.80, p = .43, sex, (1, N =
151) = .05, p = .83, phi = .03, or ethnicity/race (i.e., black and white), (1, N = 151) = 1.70, p =
.19, phi = -.14.
Further analyses, t-tests for continuous variables and chi-square tests for independence
(with Yates Continuity Correction) for categorical variables, were conducted to investigate
possible group differences across several variables, as shown in Tables 8 and 9. Variables
assessed included the following: employment, relationship, and smoking status, abuse history,
substance abuse, family substance abuse, education, pain diagnoses, mental health diagnoses,
pain rating at the time of the appointment, duration of chronic pain, number of times married,
number of children, as well as total scores for self-reported pain severity (MPQSF), pain
catastrophizing (PCS), misuse or diversion behaviors (SOAPP-R), depression symptoms (BDIII), pain disability (PDI), and fear of movement (TSK). . Patients who were more likely to be
prescribed an opioid included those who were married or with a long-term partner and those
patients who reported higher level of education. Patients who were less likely to be prescribed an
opioid included those reporting some form of abuse, a history of substance abuse, a higher pain
rating at the time of the evaluation, as well as patients with higher scores on the PCS, SOAPP-R,
and BDI-II.
Research Question 2
Did the patient’s opioid risk status affect whether a physician prescribed an opioid
at the first appointment following the evaluation? The dependent variable, opioid
prescribing, was constructed as a “yes/no” dichotomous indicator of whether or not a patient was
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prescribed an opioid following an opioid risk evaluation. Patients prescribed an opioid at the
first appointment following the opioid risk evaluation were coded as YES (1) and patients not
prescribed an opioid or did not return following the opioid risk evaluation were coded as NO (0).
The dependent variable, risk status, was coded with High = 1, Moderate and Moderate-High = 2,
and Low and Low-Moderate = 3. See Table 11 for the number of patients in each risk category
by opioid prescribing group.
In order to examine the predictive association between opioid risk status (i.e., low/lowmoderate, moderate/moderate-high, high) and opioid prescription decision (i.e., prescribed, not
prescribed), a binary logistic regression was conducted. The overall model was statistically
significant, (1, N = 151) = 37.10, p < .001, indicating that the model was able to distinguish
between patients who were prescribed an opioid and those who were not. The model as a whole
explained between 21.8% (Cox and Snell R square) and 29.3% (Nagelkerke R squared) of the
variance in opioid prescribing, and correctly classified 72.2% of cases. The Wald statistic
indicated that the risk status variable significantly predicted opioid prescribing. The
unstandardized regression coefficient is positive which indicates a positive relation with the
probability of "success" (i.e., when risk status decreases probability of being prescribed an opioid
increases). Additionally, when the probability of being prescribed an opioid is more than the
probability not being prescribed an opioid, then the odds ratio will be greater than 1, as it is in
the current analysis. Therefore, the odds of being prescribed an opioid increased 4.22 times for
each level decrease in risk status. See Table 12 for more information.
Research Question 3
What other variables influenced physician opioid prescribing behavior? Next, a
series of univariate logistic regressions (i.e., each analysis included one predictor variable) was
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utilized to examine potentially significant variables in predicting physician opioid prescribing to
determine which factors should be included in the final model (Agresti, 2007). Based on the
literature, there were 21 factors independently reviewed and considered for inclusion in analyses.
These variables were: patient’s sex, patient’s age, substance abuse history, familial substance
abuse history, mental health diagnoses, current smoking status, employment status, history of
abuse, relationship status, education, pain diagnoses, Board of Pharmacy review, urine drug
screen, physician training level, physician sex, as well as total scores on the SFMPQ, PCS, PDI,
SOAPP-R, TSK, and BDI-II. The Board of Pharmacy review and urine drug screen variables
were excluded from analyses as both variables had inadequate data for inclusion in analyses with
the urine drug screen missing in 69.5% of the sample and the Board of Pharmacy review missing
in 79.5% of the sample. This information was missing as it was not consistently reported in the
patient’s electronic medical record, which may be due to the patient not undergoing a urine drug
screen or Board of Pharmacy review, or physicians not reporting this information in the medical
record, as it only recently was required by West Virginia state law in July 2012 (West Virginia
State Code, 2012). All 19 other variables were included in this stage of analysis. The variables
that made a unique statistically significant contribution to the model at the p < .05 level were
substance abuse history, history of abuse, relationship status, education, and total scores on the
SOAPP-R, PCS, and BDI-II. Due to the number of variables significant at the 0.05 level, values
at the 0.25 level were not considered as there would not be enough power to adequately assess
these variables in further analyses (Bendel & Afifi, 1977; Mickey & Greenland, 1989). See
Table 13 and 14 for pertinent information regarding these variables.
Based on the significant factors discovered in the series of univariate binary logistic
regressions, a multivariate logistic regression was conducted. The variables of substance abuse
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history, history of physical abuse, relationship status, education, and total scores on the SOAPPR, PCS, and BDI-II were entered as the independent variables, and whether the physician
prescribed an opioid at the first appointment following the opioid risk evaluation as the
dependent variable. Risk status was not included in this analysis in order to determine the
contribution of these other variables to the predictive model. After examining the overall model
and variable statistics, the variables of history of abuse, education, and total scores on the
SOAPP-R, PCS, and BDI-II were removed from the analyses as they did not account for a
significant amount of the variance; however, substance abuse history remained statistically
significant. When removing substance abuse history from the analyses, the overall model
remained significant; however, none of the predictor variables were significant. Therefore, the
final model included substance abuse history and risk status, but no other predictor variables.
See Table 15 for additional information on the variables and model.
Research Question 4
How did the inclusion of opioid risk status and other significant variables, as
determined in research question 3, affect whether a physician prescribes an opioid at the
first appointment following the opioid risk evaluation? To examine the unique contribution
of risk status in the prediction of opioid prescribing, a hierarchical logistic regression analysis
was conducted. In step one, opioid prescribing was the dependent variable, and substance abuse
history was included as a control variable. Due to the lack of significance within the binary
logistic regressions for age and sex, these variables were not included as control variables. In
step two, the risk status variable was entered into the equation.
The results of step one indicated that the model was statistically significant (2, N =
151) = 20.44, p < .001, with substance abuse history being statistically significant at the p < .001
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level. In step two, risk status was entered into the regression equation. The overall model was
statistically significant, (2, N = 151) = 39.61, p < .001, indicating that the model was able to
distinguish between patients who were prescribed an opioid and patients who were not. The
model as a whole explained between 23.1% (Cox and Snell R square) and 31.1% (Nagelkerke R
squared) of the variance in opioid prescribing, and correctly classified 70.9% of cases. This
additional step was significant,  (1, N = 151) = 19.17, p < .001, indicating that the added risk
status variable significantly improved the model. Wald statistics indicate that only the risk status
variable was significant in the final model (p < .001), and substance abuse history was no longer
significant (p = .11). The odds of being prescribed an opioid increased 3.40 times for each level
decrease in risk status. See Table 16 for additional information.
The inclusion of substance abuse history in the model minimally reduces the percentage
of correctly classified patients from 72.2% to 70.9%. Additionally, when the analysis was
conducted with only substance abuse history as the predictor variable, the model was significant,
 (1, N = 151) = 20.44, p < .001, substance abuse history was significant at the p < .001 level,
and the model correctly classified 69.5% of the patients. It appears that substance abuse history
parallels the predictive utility of risk status, when included independently. While these variables
both significantly predict opioid prescribing independently, it was decided that the final model
only should include risk status as it was the variable of interest; it remained significant when
included with substance abuse history, and substance abuse history did not improve the overall
model. See Table 12 for the final model.
The overall predictive utility of the final model can be found using the Receiver
Operating Characteristic (ROC) curve analysis (Metz, 1978; Zweig & Campbell, 1993) with
opioid prescribing being the state variable and the predicted probabilities as the test variable.
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This test demonstrates how well the model classifies individuals and selects a “cut-off” point to
maximize sensitivity and specificity. To interpret the area under the curve (AUC) statistic, an
AUC of 1 represents a perfect classification and an AUC of 0.5 represents the same accuracy as
chance. A general guide is that fair-to-excellent accuracy is achieved when AUC ≥ 0.7 (i.e., .901 = excellent, .80-.90 = good, .70-.80 = fair, .60-.70 = poor, and .50-.60 = inclusive/little to no
utility; Hanley & McNeil, 1982; Zou et al., 2003). The ROC curve analysis showed that the area
under the ROC curve was .76 (76.3%; CI = 69-84%). The model is significantly better than
chance, in terms of classifying whether or not a patient was prescribed an opioid, p < .001.
Exploratory Analyses
An area of concern was the differences between residents’ and attending physicians’ use
of the risk status information. Due to the selection bias which exists when referring patients (i.e.,
residents are required, attending physicians are strongly encouraged), it was unclear how
attending physicians may refer patients and if they would utilize the opioid risk evaluation in
their prescribing decision. Based on the sample of 151 patients, 49 were referred by attending
physicians and 102 by resident physicians. (See Tables 2 and 17 for additional information about
referrals by physician training.) The 49 referrals came from 13 different attending physicians
and the 102 referrals came from 27 different resident physicians. These numbers are uneven,
though there are relatively equivalent numbers of resident and attending physicians on staff (i.e.,
~20 of each). A chi-square test for independence (with Yates Continuity Correction) was
conducted to determine if there was an association between risk status and physician training
level. This relationship was not significant, (2, N = 151) = .69, p = .71. Next, a binary
logistic regression was conducted with opioid prescribing as the outcome variable and physician
training level as the predictor variable. Neither the overall model,  (1, N = 151) = 1.49, p =
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.22, nor the Wald statistic, Wald = 1.47, p = .23, were statistically significant. This outcome
suggests that the model was not able to distinguish between patients who were prescribed an
opioid and patients who were not, based on physician training level alone.
Additionally, a secondary concern involved the different levels of training within the
psychology team (i.e., graduate students, predoctoral interns, postdoctoral fellows, and licensed
psychologists) assigning the risk status and the potential for bias when assigning. In order to
examine this concern, a chi-square test for independence (with Yates Continuity Correction) was
conducted between opioid risk status (i.e., low/low-moderate, moderate/moderate-high, high)
and evaluator training level (i.e., graduate students, predoctoral interns, postdoctoral fellows,
licensed psychologists). There was no significant association between opioid risk status and
evaluator training level,  (6, N = 151) = 10.31, p = .12, phi = .26. See Table 1 for frequencies
and percentages of assigned risk status by evaluator training level. Additional analyses and
examination are necessary to fully understand the role of the evaluator and the influence it has on
opioid risk status and prescribing; however, it does not appear to be an issue within this sample.
Discussion
Few studies have addressed opioid prescribing behaviors beyond patient demographic
attributes. Moreover, little research has addressed how psychological evaluation, and assignment
of risk status, may contribute to decisions by physicians in prescribing for the treatment of
chronic pain. The current study has several interesting findings regarding opioid prescribing and
patient characteristics. Patients prescribed an opioid were more likely to be married or with a
long term partner and have a higher level of education. Patients not prescribed an opioid were
more likely to report a higher pain rating at the time of the evaluation, a history of abuse or
substance abuse, or have higher total scores for pain catastrophizing (PCS), misuse or diversion
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behaviors (SOAPP-R), and depression symptoms (BDI-II). Additionally, the best predictors of
opioid prescribing were substance abuse and opioid risk status, with patients with no history of
substance abuse and lower risk status being more likely to be prescribed an opioid. The finding
that substance abuse history is related to opioid prescribing corroborates previous study findings
(e.g., Pergolizzi, 2012; Turk, Swanson, & Gatchel, 2008); however, the influence of opioid risk
status on opioid prescribing is an interesting and important finding. Interestingly, age, sex, and
ethnicity/race were not significant predictors of opioid prescribing, suggesting that providing
physicians with additional information about their chronic pain patient’s potential for opioid
abuse may act to reduce prescribing bias based on demographic factors as found in previous
studies.
Overall Findings
The first aim of the current investigation was to explore the differences between patients
prescribed or not prescribed opioids. Patients prescribed and not prescribed an opioid were not
significantly different based on age, sex, race, employment status or smoking status, mental
health diagnoses, pain diagnoses, family history of substance abuse, number of children or times
married, duration of chronic pain, or total scores on measures of pain severity (MPQSF), pain
disability (PDI), and fear of movement (TSK). The lack of demographic differences between
these two groups is alone an interesting finding. Previous research has demonstrated that nurses
and physicians often are influenced by age, sex, and race when making prescribing decisions
(Burgess et al., 2008; Hirsh, George, & Robinson, 2009; Olsen, Daumit, & Ford, 2006; Pletcher,
Kertesz, Kohn, & Gonzales, 2008; Tamayo-Sarver, Hinze, Cydulka, & Baker, 2003; Weisse,
Sorum, Sanders, & Syat, 2001). The current study may not have detected differences in these
demographic factors due to having a smaller sample size (N = 151) than other similar
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investigations (e.g., N = 382 in Burgess et al., 2008), especially in regard to race. Interestingly,
only one of the studies just mentioned utilized patients presenting to a primary care office (i.e.,
Weisse, Sorum, Sanders, & Syat, 2001) with a sample size of 111, and this investigation did not
find any significant differences in prescribing based on patient sex or ethnicity/race, but did find
a significant interaction between physician sex and gender/racial and ethnicity cues. The other
investigations just mentioned were conducted utilizing patients presenting to emergency
departments for care (i.e., Pletcher, Kertesz, Kohn, & Gonzales, 2008; Tamayo-Sarver, Hinze,
Cydulka, & Baker, 2003) or did not occur with “real” patients and instead utilized virtual
humans or had physicians read paper vignettes about patients (i.e., Burgess et al., 2008; Hirsh,
George, & Robinson, 2009). Lastly, Olsen, Daumit, and Ford (2006) based their findings on the
National Ambulatory Medical Care Survey, which includes both ambulatory and outpatient
departments. The lack of significance between age, sex, and ethnicity/race found in this
investigation and the study conducted by Weisse et al. (2001) suggests that there may be
something unique about Family Medicine patient populations; however, additional analyses are
necessary to determine if there were any interaction effects within the current investigation.
The groups differed based on their pain rating at the time of the opioid risk evaluation,
history of abuse or substance abuse, relationship status, level of education, and scores on the
PCS, SOAPP-R, and BDI-II. Patients not prescribed an opioid were more likely to have higher
pain ratings at the time of the evaluation, report a history of abuse, be single or divorced, and
have higher scores on the PCS, SOAPP-R, and BDI-II. These results are not surprising as all of
these variables are considered when deciding risk status, and have associations with opioid or
substance abuse in the literature. A patient presenting to clinic with these characteristics (i.e.,
anxious/depressed, exhibiting misuse or diversion behaviors) likely is more complicated than a
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patient without these particular problems, and may signal a higher risk to the evaluator or
physician. It is difficult to determine how the patient interacted with the psychology team or
physician, but research findings suggest that patients with a more complicated presentation are
more difficult to treat (Matthias et al., 2010), and these characteristics may be the most apparent,
as compared to other variables that were examined.
The second aim of this study was to examine the influence of opioid risk status on opioid
prescribing. Patient care has improved and healthcare costs have been reduced with the
inclusion of interdisciplinary integrated care (Blumenthal et al., 2005; van Orden, Hoffman,
Haffmans, Spinhoven, & Hoencamp, 2009); however, it was unclear if physicians incorporated
the recommendations from other professionals into their decision making process and how it
may affect their treatment of chronic pain patients. The results of this aim suggest that
physicians integrate the recommendations of the psychological team into their decision making
process when prescribing opioid analgesics. It is possible that having a variety of factors
consolidated into a singular risk status may be beneficial to physicians in understanding their
patient’s opioid abuse potential as many physicians lack training in discerning opioid abuse and
diversion (Matthias et al., 2010; Richeimer, 2005), and having to consider multiple risk factors,
instead of a singular risk status may be overwhelming, time consuming, and unhelpful.
The third aim was to determine if any other factors outlined in the literature were
predictive of opioid prescribing. After identifying risk status as a significant predictor, it was
important to further evaluate other variables influence on opioid prescribing. Several variables
significantly predicted opioid prescribing as expected based on the literature, specifically history
of substance abuse, level of education, relationship status, and scores on the SOAPP-R, BDI-II,
and PCS. These variables have been identified as factors related to potential opioid abuse and
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therefore were expected to be significant predictors (Breitbart et al., 1997; Chou, 2009; Passik,
Messina, Golsorkhi, & Xie, 2010; Pergolizzi et al., 2012; Portenoy, 1996; Rice et al., 2012; Turk,
Swanson, & Gatchel, 2008; Weaver & Schnoll, 2002; Ziegler, 2005). Interestingly, patients’
history of abuse also significantly predicted opioid prescribing, with patients reporting a history
of physical or sexual abuse being less likely to be prescribed an opioid. History of preadolescent
sexual abuse has been identified as a potential risk factor for substance abuse (Kendler, Bulik,
Silberg, Hettema, Myers, & Prescott, 2000; Mullen, Martin, Anderson, Romans, & Herbison,
1993), but has not been associated with opioid prescribing or specifically for opioid abuse. For
this study, the patients’ history of abuse included both sexual and physical abuse identified by
the patient, demonstrating the potential influence of this history on opioid prescribing. It is
unclear whether these patients should or should not be prescribed an opioid; however, a history
of abuse has been associated with mental health and substance abuse problems (Beitchman et al.,
1992; Mullen, Martin, Anderson, Romans, & Herbison, 1996; Nikulina, Widom, & Brzustowicz,
2012), as well as a number of medical problems, including obesity, chronic headaches, chronic
pelvic pain, somatization, and certain surgical procedures (e.g., hysterectomy; Felitti, 1991; Irish,
Kobayashi, & Delahanty, 2010; Longstreth, 1994; Springs & Friedrich, 1992). When
considering the potential psychological comorbidities associated with abuse, it is possible that
patients presenting with a history of abuse also had additional problems. This presentation may
result in the psychology team increasing the patient’s risk status and recommending alternative
treatments prior to prescribing opioids.
The final aim was to utilize the significant factors to develop a predictive model.
Unexpectedly, while many factors were significant predictors independently, when added to the
full model, these factors no longer were significant. Results of multivariate logistic regression
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analysis demonstrated that the predictor variables likely share variance with the risk status
assigned to each patient as many of these variables were utilized to determine said status;
however, substance abuse history remained significant until included with risk status. Therefore,
the best predictor of opioid prescribing appears to be the risk status assigned by the
psychological team, as well as substance abuse history, when considered independently;
however, when included alone, risk status demonstrated better model fit than when included with
substance abuse or substance abuse on its own. These results suggest the effectiveness in
providing supplemental information to physicians to aid in opioid prescribing decisions, and may
act to reduce prescribing bias based on demographic factors (i.e., age, ethnicity/race, gender).
Physicians have reported having less training and confidence in treating chronic pain and
identifying opioid abuse and diversion (Glajchen, 2001; Matthias, 2010; Richeimer, 2005). By
providing physicians with a condensed version of the various risk factors through the singular
risk status, they are able to more easily utilize evidence-based factors in their decision-making
process, potentially reduce prescribing bias, and possibly avoiding conflict with their patients.
Exploratory Analyses
Selection bias was thought to be a potential area of concern due to the policy related to
referrals to the psychology team. The WVU Family Medicine protocol requires resident
physicians to refer all patients requesting or being considered for long-term opioid therapy;
however, attending physicians are strongly encouraged, but not required. While there were more
referrals from resident physicians, there was no significant difference in opioid prescribing based
on physician training level. Additionally, after examining the crosstabulations between
physician training level and risk status, the outcome of the evaluations for the referred patients
was equivalent across risk status and physician training level, with no significant differences.
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This finding suggests that when attending physicians refer patients for an evaluation the patients
likely are not all psychosocially complex, as previously assumed. The attending physicians refer
an array of patients, or at least that is how it appears post opioid risk status. See Table 17 for this
information.
A secondary concern involved the different levels of training within the psychology team
(i.e., graduate students, predoctoral interns, postdoctoral fellows, and licensed psychologists)
assigning the risk status and the potential for bias when assigning. It is possible that there is
variability in how the evaluators’ assigned risk status as there is an element of clinical judgment
inherent in each evaluation; however, there was no significant difference between opioid risk
status and evaluator training level. This finding suggests that within the study sample, evaluators
from the four training levels assigned risk statuses in relatively equivalent numbers.
Limitations and Strengths
Due to the retrospective design of the current investigation, there was little control over
what was asked of the patients and what was included in the opioid risk evaluation. While there
was relative consistency across the format of the evaluations, some information had to be
extrapolated from the patient’s medical record. Unfortunately, some patients neglected to fully
complete questionnaires resulting in missing data, which could not be recovered. In addition, the
information about opioid prescribing was based on the decision made at the next appointment
following the opioid risk evaluation, and does not account for any changes, which may have
occurred, following that appointment or other classes of medications prescribed. Lastly, due to
insufficient data, the information about patients’ Board of Pharmacy review and urine drug
screens were unable to be analyzed. It seemed that the majority of patients in this sample did not
have the Board of Pharmacy review noted in their medical record, though it seemed to increase
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in the evaluations conducted following July 2012, which coincides with new guidelines for
reporting (West Virginia Code, 2012). In regard to the urine drug screen, many patients did not
have an initial screen in their records, and few patients had any follow-up screens. Inclusion of
this information may have modified the results; however, due to the lack of information in the
medical record, it may be that physicians were not utilizing this information when prescribing.
Unfortunately, there was little information about the opioid prescribing practices of
physicians in the clinic prior to the institution of the opioid risk evaluations in late 2010. It could
be assumed that the opioid prescribing practices were likely less stringent as it was a different
socio-political climate and opioid abuse was not as evident at that time. Only in the past four
years has the focus shifted to prescribing less and more carefully and creating more stringent
guidelines for chronic opioid therapy through the recommendation of major pain associations
(i.e., Neuropathic Pain Special Interest Group of the International Association for the Study of
Pain; European Federation of Neurological Societies Task Force; Attal et al., 2010; Dworkin et
al., 2010). Therefore, physicians may have been more lenient with prescribing; however, there is
not definitive information available to determine if this assumption is accurate or to determine
what was predictive of opioid prescribing at that time.
The WVU Department of Family Medicine psychology team has a specific format for
opioid risk evaluations based upon the current research available regarding opioid abuse and
misuse; however, the final decision of assigning a risk status is decided utilizing a variety of
information, as well as clinician judgment. It is unclear how each clinician may be utilizing the
information or which information is weighted more heavily when assigning risk status. As a
result, there is an inherent amount of variation within the opioid risk evaluations.
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Information from the physicians’ perspective regarding what he or she consciously
considers when prescribing opioids would have been a helpful addition to the current data. By
understanding what the physician considers and comparing it to the current information,
potential discrepancies could have been identified. Additionally, it would be interesting to
examine how heavily the physicians weighed various aspects of a patient’s presentation when
prescribing, especially the opioid risk status. Unfortunately, due to the nature of the current
investigation, obtaining information from physicians would have been difficult and tainted by the
retrospective design. Some resident physicians have graduated from the program making them
unavailable for questioning and unless the physicians were asked to evaluate cases on a patientby-patient basis it may lead to overgeneralizations or inaccurate self-critiques on their
prescribing behaviors.
Using patients at a family medicine clinic was a particular strength of this study;
however, due to the ethnic/racial makeup of West Virginia, lack of diversity was a limitation.
The current study would benefit from the inclusion of different races and ethnicities as the
sample was 96.7% white and 3.3% black. This limitation is consistent with the ethnic/racial
profile of West Virginia (i.e., 94% Caucasian, 6% Other; U.S. Census Bureau, 2012), and should
be addressed in future research.
Future Research
The current project is the first known study of the influence of interdisciplinary
recommendations on opioid prescribing. With the growing emphasis on patient-centered care
and interdisciplinary treatment, future work in this same area likely would improve professional
interactions and team based approaches to treating complicated chronic pain patients. One future
direction of research might include designing a prospective longitudinal study that includes
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qualitative information, specifically the physicians’ perspective when prescribing to determine
which factors are considered and to what degree when making difficult prescribing decisions.
Additionally, certain variables, which likely are influential in prescribing (i.e., Board of
Pharmacy review, urine drug screen), often were not mentioned or not completed for patients
making it difficult to determine if physicians utilized this information when prescribing. In
2012, West Virginia introduced a new law requiring the inclusion of this information in medical
records for patients prescribed long term opioid medication (West Virginia Code, 2012). This
information should be included in future research to determine each variables predictive value in
opioid prescribing, especially as it relates to risk status.
Other future work in this area may further examine the opioid risk evaluations to create a
more consolidated approach and remove some of the inherent variation due to clinician
judgment. By deconstructing the evaluation, clinicians may be able to create a screener to
determine which patients can be assessed through a brief evaluation instead of the lengthy full
version. This assessment of the evaluation material also may help to focus the opioid risk
evaluations on the factors that seem to be most indicative of opioid misuse and abuse.
Additionally, inclusion of feedback from physicians that specifies which information they are
likely to attend to when prescribing may allow clinicians to create a shorter, more concise report
for physician use. Lastly, it is necessary to determine the accuracy of the opioid risk status
through future follow-up with patients. This information could be determined through Board of
Pharmacy reviews, urine drug screens, and brief follow-up screenings with patients. This
information may prove difficult to obtain as some patients may choose to receive care elsewhere;
however, it could be beneficial in understanding the static and dynamic risk factors over time.
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After better understanding physician perspectives and the evaluation itself, a cost
analyses would be a viable next step to better understand the impact on the larger healthcare
system. Previous research has shown that integrated care reduces treatment time, and results in
fewer appointments and lower costs than traditional patient referral to offsite mental health
centers (van Orden et al., 2009); however, it is unclear what impact these evaluations may have
on costs associated with the treatment of chronic pain. By better understanding the potential
influence on costs, the feasibility of utilizing risk evaluations could be assessed.
Conclusions
The aims of this study were to: (a) explore the differences between patients prescribed or
not prescribed opioids, (b) examine the influence of opioid risk status on opioid prescribing, (c)
determine if any other factors outlined in the literature were predictive of opioid prescribing, and
(d) utilize these factors to develop a predictive model. To achieve these goals, electronic
medical record reviews were conducted on 151 chronic pain patients seeking long term opioid
therapy. Using a series of univariate logistic regressions, several factors were identified as being
significantly predictive of opioid prescribing; however, only two variables remained significant
when included in the full model, substance abuse and risk status.
With the current socio-political agenda in regard to healthcare, (i.e., focus on reducing
opioid abuse and overdose deaths, as well as emphasizing interdisciplinary care), the current
investigation provides important information about physicians’ opioid prescribing and utilization
of other professionals’ recommendations. Based on the results, opioid prescribing was
significantly influenced by the opioid risk evaluation conducted by the psychology team at the
WVU Department of Family Medicine. This information is promising for interdisciplinary
treatment teams as it seems physicians integrate the professional assessment of other experts into
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their decision making process. Additionally, it suggests that physicians can modify their bias of
prescribing based on age, ethnicity/race, and sex, as found in other studies, to instead rely on
research-based opioid risk evaluations. The opportunity for additional information in an area in
which physicians often lack training and describe having difficulty providing treatment
(Bendtsen, Hensing, Ebeling, & Schedin, 1999; Bertakis, Azari, & Callahan, 2003; Matthias et
al., 2010) may allow for physicians to utilize information from other professionals to learn about
alternative treatment options in the process.
What remains unanswered by the current study is if this modification to utilize opioid risk
status for prescribing is an improvement for patient care, a means to protect the physician from
litigation, or a potential bias against patients that may have psychosocial problems? Patients that
are high risk for opioid abuse still can be prescribed opioid medication (Weaver & Schnoll,
2002), but the inherent risks for the patient and physician increase resulting in increased scrutiny
of the patient and intensified monitoring responsibilities for the physician. The increased
demand on physician time may lead physicians to simply deny prescriptions for those patients
that may benefit, even if high risk. Alternatively, the utilization of risk status and expert pain
recommendations may encourage physicians to try alternative treatment options (e.g.,
antidepressant or anticonvulsant medication, physical therapy, psychotherapy) prior to
prescribing opioid medication, which arguably is a better first line of treatment than chronic
opioid therapy and may lead to improved patient functioning that is unlikely to be achieved with
chronic opioid therapy alone.
The current study illustrates the effectiveness of providing physicians with supplemental
information, specifically in an area in which they tend to have less training and confidence (i.e.,
chronic pain treatment, identifying opioid abuse and diversion). By utilizing risk status to aid
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physician’s prescribing decisions, the inclusion of evidence-based factors into their decisionmaking process is simplified. Physicians can rely on the expert evaluation of a colleague, while
potentially eliminating some of their own inherent bias and possibly improving patient care. On
a larger systems level, understanding how opioid risk status and other factors affect physicians’
opioid prescribing, may reveal how to modify physician bias not only in the realm of opioid
prescribing, but other aspects of patient care. If the inclusion of interdisciplinary care and
collaborative treatment reduces physician bias and eases the decision-making process, it lends
the physician more time to spend on other aspects of patient care or other cases. With the influx
of patients into primary care expected with the introduction of the Affordable Care Act,
increasing physician efficiency and providing support is an essential part of helping to make this
policy successful. Thus, opioid risk evaluations demonstrate one aspect of support that
psychology can provide to physicians and the healthcare system as a whole.
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Table 1
Frequencies and Percentages of Assigned Risk Status by Evaluator Training Level
Risk Status

Graduate
Student
Total (%)

Predoctoral
Intern
Total (%)

Postdoctoral
Fellow
Total (%)

Licensed
Psychologist
Total (%)

Low/Low-Moderate

13 (48.1)

9 (36.0)

6 (17.6)

22 (33.8)

Moderate/Moderate-High

7 (25.9)

9 (36.0)

13 (38.2)

29 (44.6)

High

7 (25.9)

7 (28.0)

15 (44.1)

14 (21.5)

Total

27 (100/17.9)

25 (100/16.6)

34 (100/22.5)

65 (100/43.0)

Note. In the three risk status levels, the number in parentheses represents the percent within each
column group (e.g., 48.1% = percent of Graduate Students with evaluation outcomes in the
low/low-moderate risk category). The numbers in parentheses for each Total reflect the group
(column) total percentage, followed by the percentage of the overall total number of patients
evaluated by each column group (e.g., 17.9% = percent of total patients evaluated by a Graduate
Student).
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Table 2
Frequencies and Percentages of Psychological Evaluator/Physician Training Level by Opioid
Prescribing
Evaluator/Physician Training Level

Yes, Prescribed Opioid
Total (%)

No, Not Prescribed Opioid
Total (%)

Graduate Student

17 (19.3)

10 (15.9)

Predoctoral Intern

20 (22.7)

5 (7.9)

Postdoctoral Fellow

20 (22.7)

14 (22.2)

Licensed Psychologist

31 (35.2)

34 (54.0)

88 (100/58.3)

63 (100/41.7)

Resident

32 (36.4)

17 (27.0)

Attending

56 (63.6)

46 (73.0)

88 (100/58.3)

63 (100/41.7)

Total

Total

Note. For the variables in each row (i.e., psychologist training level followed by physician
training level), the number in parentheses represents the percent within each column group (e.g.,
19.3% = percent of patients prescribed an opioid who had evaluations with a Graduate Student).
The numbers in parentheses for each Total reflects the group (column) total percentage, followed
by the percentage of the overall total number of patients prescribed or not prescribed an opioid
(e.g., 58.3% = percent of total patients prescribed an opioid).
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Table 3
Inspecting Multicollinearity Assumption through Collinearity Statistics
Tolerance

Variance Inflation Factor

Sex

.73

1.37

Race

.88

1.14

Age

.70

1.44

Risk Status

.46

2.17

Abuse history

.65

1.53

Smoking status

.78

1.29

Substance abuse

.58

1.71

Family substance abuse history

.71

1.40

Employment status

.75

1.33

Relationship status

.70

1.42

Education

.82

1.21

Mental health diagnoses

.84

1.19

Pain diagnoses

.90

1.11
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Table 3 (continued)
Inspecting Multicollinearity Assumption through Collinearity Statistics
Tolerance

Variance Inflation Factor

Pain rating (0-10)

.63

1.59

Duration of chronic pain

.73

1.36

Physician sex

.84

1.19

Physician training level

.87

1.15

SFMPQ

.61

1.65

PCS

.42

2.37

PDI

.62

1.60

SOAPP-R

.37

2.67

TSK

.56

1.80

BDI-II

.39

2.56

Note. SFMPQ = Short Form-McGill Pain Questionnaire; PCS = Pain Catastrophizing Scale; PDI
= Pain Disability Index; SOAPP-R = Screener and Opioid Assessment for Patients with Pain,
Revised; TSK = Tampa Scale for Kinesiophobia; BDI-II = Beck Depression Inventory-II
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Table 4
Bivariate Correlations between Questionnaires
SF-MPQ

PCS

PDI

SOAPP-R

PCS

.43**

PDI

.35**

.44**

SOAPP-R

.33**

.56**

.33**

TSK

.28**

.40**

.40**

.23*

BDI-II

.33**

.50**

.38**

.65**

TSK

.29**

Note. * = significant at the <.05 level; ** = significant at the <.001 level; SFMPQ = Short FormMcGill Pain Questionnaire; PCS = Pain Catastrophizing Scale; PDI = Pain Disability Index;
SOAPP-R = Screener and Opioid Assessment for Patients with Pain, Revised; TSK = Tampa
Scale for Kinesiophobia; BDI-II = Beck Depression Inventory-II
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Table 5
Missing Values by Self-Report Questionnaire
Questionnaire

Number of missing items (%)

Short Form-McGill Pain Questionnaire

90 (3.9%)

Pain Catastrophizing Scale

86 (4.4%)

Pain Disability Index

43 (4.1%)

Screener and Opioid Assessment for Patients with Pain-Revised

169 (4.7%)

Tampa Scale for Kinesiophobia

209 (8.1%)

Beck Depression Inventory-II

236 (7.4%)
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Table 6
Patient Characteristics and Predictor Variables Descriptive Statistics for Study Sample
(Continuous Variables)
Mean

Standard Deviation

Minimum

Maximum

Age

48.2

11.1

19

80

Pain rating

7.6

1.8

0

10

Duration of pain (years)

10.7

9.5

.25

51

Times married

1.5

1.1

0

7

Children

2.3

1.7

0

10

SFMPQ

21.4

9.7

0

45

PCS

25.6

13.8

0

52

SOAPP-R

17.2

11.3

0

74

BDI-II

13.8

10.2

0

53

PDI

40.4

15.0

0

70

TSK

37.9

11.7

17

74

Note. SFMPQ = Short Form-McGill Pain Questionnaire; PCS = Pain Catastrophizing Scale;
SOAPP-R = Screener and Opioid Assessment for Patients with Pain, Revised; BDI-II = Beck
Depression Inventory-II; PDI = Pain Disability Index; TSK = Tampa Scale for Kinesiophobia
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Table 7
Patient Characteristics and Predictor Variables Descriptive Statistics for Study Sample
(Categorical Variables)
Total

Percentage

Female

62

41.1%

Male

89

58.9%

White

146

96.7%

Black

5

3.3%

Low/Low-Moderate

50

33.1%

Moderate/Moderate-High

58

38.4%

High

43

28.5%

Employed

70

46.4%

Disabled

81

53.6%

Single/Divorced

84

55.6%

Married/Partnered

67

44.4%

Yes

90

59.6%

No

61

40.4%

Yes

48

31.8%

No

93

61.6%

Sex

Race

Risk Status

Employment

Relationship

Smoking Status

Abuse History
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Table 7 (continued)
Patient Characteristics and Predictor Variables Descriptive Statistics for Study Sample
(Categorical Variables)
Total

Percentage

<High School

29

19.2%

High School/GED

65

43.0%

Associate’s/Some College

30

19.9%

Bachelor’s or higher

17

11.3%

Yes

57

37.7%

No

94

62.3%

Yes

58

33.8%

No

51

38.4%

Resident

102

67.5%

Attending

49

32.5%

Education

Substance Abuse History

Family Substance Abuse History

Physician Training Level
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Table 8
Differences in Demographic and Psychosocial Variables by Opioid Prescribing Group
(Continuous Variables)
Not Prescribed
Opioid
M (SD)

Prescribed
Opioid
M (SD)

t (149)

p

47.3 (11.2)

48.8 (11.0)

-.80

.43

8.0 (1.8)

7.4 (1.7)

1.95

.05

10.6 (10.1)

10.8 (9.1)

-.15

.88

Times married

1.6 (1.3)

1.4 (1.0)

1.14

.26

Children

2.4 (1.8)

2.2 (1.6)

.65

.43

SFMPQ

22.0 (9.8)

21.1 (10.0)

.57

.57

PCS

29.6 (12.4)

22.7 (14.1)

3.13

.002

SOAPP-R

20.0 (13.4)

15.2 (8.9)

2.61

.009

BDI-II

16.0 (12.6)

12.4 (8.4)

2.04

.04

PDI

42.2 (13.7)

39.0 (16.2)

1.25

.21

TSK

38.6 (10.6)

37.9 (9.9)

.39

.70

Age
Pain rating (0-10)*
Duration of pain (years)

Note. *Pain ratings measured from 0-10, with 10 being the worst pain; SFMPQ = Short FormMcGill Pain Questionnaire; PCS = Pain Catastrophizing Scale; SOAPP-R = Screener and Opioid
Assessment for Patients with Pain, Revised; BDI-II = Beck Depression Inventory-II; PDI = Pain
Disability Index; TSK = Tampa Scale for Kinesiophobia
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Table 9
Differences in Demographic and Psychosocial Variables by Opioid Prescribing Group
(Categorical Variables)
Not Prescribed
Opioid
Total (%)

Prescribed
Opioid
Total (%)

36 (57.1)

53 (60.2)



p

.05

.83

1.70

.19

.80

.37

6.13

.01

.43

.51

5.95

.02

18.75

<.001

Sex
Female
Male

27 (42.9)

35 (39.6)

White

59 (93.7)

87 (98.9)

Black

4 (6.3)

1 (1.1)

Employed

26 (41.3)

44 (50.0)

Disabled

37 (58.7)

44 (50.0)

Single/Divorced

43 (68.3)

41 (46.6)

Race

Employment

Relationship

Married/Partnered

20 (31.7)

47 (53.4)

Yes

40 (63.5)

50 (56.8)

No

23 (36.5)

38 (43.2)

Yes

27 (46.6)

21 (25.3)

No

31 (53.4)

62 (74.7)

Yes

37 (58.7)

20 (22.7)

No

26 (41.3)

68 (77.3)

Smoking Status

Abuse History

Substance Abuse

Note. For the variables in each row, the number in parentheses represents the percent within each
column group (e.g., 57.1% = percent of females not prescribed an opioid).
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Table 9 (continued)
Differences in Demographic and Psychosocial Variables by Opioid Prescribing Group
(Categorical Variables)
Not
Prescribed
Opioid
Total (%)

Prescribed
Opioid
Total (%)

25 (62.5)

33 (47.8)



p

1.64

.20

10.75

.01

.28

.99

.51

.47

Family
Substance Abuse
Yes
No

15 (37.5)

36 (52.2)

<High School

20 (33.3)

9 (11.1)

High School/GED

24 (40.0)

41 (50.6)

Associate’s/Some College

11 (18.3)

19 (23.5)

5 (8.3)

12 (14.8)

Musculoskeletal

26 (41.3)

38 (43.2)

Headache/Musculoskeletal

15 (23.8)

19 (21.6)

Abdominal/Chest

8 (12.7)

13 (14.8)

Neuropathic/Musculoskeletal

7 (11.1)

9 (10.2)

Chronic Widespread Pain

7 (11.1)

9 (10.2)

Yes

41 (65.1)

51 (58.0)

Education

Bachelor’s or higher
Pain Diagnoses

Mental Health
Diagnoses

No

22 (34.9)

37 (42.0)

Note. For the variables in each row, the number in parentheses represents the percent within each
column group (e.g., 62.5% = percent of patients with a family history of substance abuse not
prescribed an opioid).
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Table 10
Percentages of Study Sample with Various Chronic Pain Conditions and Mental Health
Diagnoses
Total (%)
Chronic Pain Conditions

Mental Health Conditions

Musculoskeletal

64 (42.4%)

Headache/Musculoskeletal

34 (22.5%)

Abdominal/Chest

21 (13.9%)

Neuropathic/Musculoskeletal

16 (10.6%)

Chronic Widespread Pain

16 (10.6%)

Any condition

101 (66.9%)

Anxiety

65 (43.0%)

Depression

79 (52.3%)

Bipolar Disorder

8 (5.3%)

Psychotic Disorder

6 (4.0%)

ADHD

5 (3.3%)

Note. ADHD = Attention-Deficit Hyperactivity Disorder
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Table 11
Frequencies and Percentages for Opioid Prescribing Group and Risk Status
Prescribed Opioid
Total (%)

Not Prescribed Opioid
Total (%)

Low/Low-Moderate

43 (48.9)

7 (11.1)

Moderate/Moderate-High

34 (38.6)

24 (38.1)

High

11 (12.5)

32 (50.8)

Total

88 (100/58.3)

63 (100/41.7)

Note. In the three risk status levels, the number in parentheses represents the percent within each
column group (e.g., 48.9% = percent of patients prescribed an opioid in the low risk category).
The number in parentheses for each Total reflects the group (column) total percentage, followed
by the percentage of the overall total number of patients prescribed or not prescribed an opioid
(e.g., 58.3% = percent of total patients prescribed an opioid).

PREDICTING OPIOID PRESCRIBING BEHAVIOR

88

Table 12
Regression Model: Predicting Opioid Prescribing with Opioid Risk Status
Predictor Variable

Risk Status

Unstandardized
Regression
Coefficient (B)

Standard Error

Odds Ratio
Exp (B)

Significance
Value (p)

1.44

.27

4.22

<.001

Note. For this model, Cox & Snell R2 = .22, Nagelkerke R2 = .29.
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Table 13
Regression Models: Binary Logistic Regressions Predicting Opioid Prescribing with Single Significant Predictors
Predictor Variable

Unstandardized
Regression
Coefficient (B)

Standard
Error

Odds Ratio
Exp (B)

Significance
Value (p)

Cox & Snell R2 /
Nagelkerke R2

Significance
Value (p)

Substance Abuse

-1.58

.36

.21

<.001

.13/.17

<.001

Abuse

-.94

.37

.39

.01

.05/.06

.01

Education

.51

.20

1.66

.01

.05/.06

.01

Relationship

.90

.35

2.47

.009

.05/.06

.01

SOAPP-R

-.04

.02

.96

.02

.05/.06

.01

PCS

-.04

.01

.96

.003

.06/.08

.002

BDI-II

-.03

.02

.97

.045

.03/.04

.04

Note. SOAPP-R = Screener and Opioid Assessment for Patients with Pain, Revised; PCS = Pain Catastrophizing Scale; BDI-II =
Beck Depression Inventory-II
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Table 14
Regression Models: Binary Logistic Regressions Predicting Opioid Prescribing with Single Non-Significant Predictors
Predictor Variable

Significance Cox & Snell R2 Significance
Value (p)
/ NagelkerkeR2
Value (p)

Unstandardized
Regression
Coefficient (B)

Standard
Error

Odds Ratio
Exp (B)

Age

.01

.02

1.01

.43

.004/.01

.42

Sex

.13

.34

1.14

.70

.001/.001

.70

Employment

-.35

.33

.70

.29

.01/.01

.29

Mental Health Condition

-.30

.34

.74

.38

.01/.01

.38

Family Substance Abuse

-.60

.41

.55

.14

.02/.03

.14

Smoking Status

-.28

.34

.76

.41

.01/.01

.41

.002/.002

.99

.003/.003

.53

Pain Category

PCP Sex

Headache/
Musculoskeletal

-.14

.43

.87

.74

Abdominal/Chest

.11

.52

1.11

.84

Neuropathic/
Musculoskeletal

-.13

.57

.88

.82

Chronic Widespread Pain

-.13

.57

.88

.82

.21

.33

1.23

.53
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Table 14 (continued)
Regression Models: Binary Logistic Regressions Predicting Opioid Prescribing with Single Non-Significant Predictors
Unstandardized
Regression
Coefficient (B)

Standard
Error

Odds Ratio
Exp (B)

Significance
Value (p)

Cox & Snell R2
/ Nagelkerke R2

Significance
Value (p)

PCP Training

-.44

.36

.65

.23

.01/.01

.22

SFMPQ

-.01

.02

.99

.57

.002/.003

.63

PDI

-.01

.01

.99

.22

.01/.02

.19

TSK

-.01

.02

.99

.74

.001/.001

.56

Predictor Variable

Note. PCP = Primary Care Physician; SFMPQ = Short Form McGill Pain Questionnaire; PDI = Pain Disability Index; TSK = Tampa
Scale for Kinesiophobia
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Table 15
Regression Model: Predicting Opioid Prescribing with All Significant Predictors, excluding Risk
Status
Predictor Variable

Unstandardized
Regression
Coefficient (B)

Standard Error

Odds Ratio
Exp (B)

Significance
Value (p)

Substance Abuse

-1.37

.41

.26

.001

Abuse

-.63

.44

.53

.15

Education

.37

.23

1.44

.11

Relationship

.63

.41

1.88

.13

BDI-II

-.004

.03

1.00

.90

SOAPP-R

-.01

.03

.99

.74

PCS

-.01

.02

1.00

.48

Note. For this model, Cox & Snell R2 = .19, Nagelkerke R2 = .26; BDI-II = Beck Depression
Inventory-II; SOAPP-R = Screener and Opioid Assessment for Patients with Pain, Revised; PCS
= Pain Catastrophizing Scale

PREDICTING OPIOID PRESCRIBING BEHAVIOR

93

Table 16
Regression Model: Predicting Opioid Prescribing with Substance Abuse and Opioid Risk Status
Predictor Variable

Substance Abuse
Risk Status

Unstandardized
Regression
Coefficient (B)
-.68

Standard Error

Odds Ratio
Exp (B)

Significance
Value (p)

.43

.51

.11

1.22

.30

3.40

<.001

Note. For this model, Cox & Snell R2 = .23, Nagelkerke R2 = .31
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Table 17
Frequencies and Percentages for Primary Care Physician Training Level and Risk Status
Attending
Total (%)

Resident
Total (%)

Low/Low-Moderate

14 (28.6)

36 (35.3)

Moderate/Moderate-High

20 (40.8)

38 (37.3)

High

15 (30.6)

28 (27.5)

Total

49 (100/32.5)

102 (100/67.5)

Note. In the three risk status levels, the number in parentheses represents the percent within each
column group (e.g., 28.6% = percent of patients assigned low/low-moderate risk referred by
attending physicians). The numbers in parentheses for each Total reflects the group (column)
total percentage, followed by the percentage of the overall total number of patients referred by
each training level (e.g., 32.5% = percent of total patients referred by attending physicians).
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Appendix A
Non-Opioid Treatments for Chronic Pain
Pharmacological treatments. Physician guidelines provide clear suggestions in the
treatment of chronic pain based on intensity (Katz, 2008). When treating mild pain,
acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs; e.g., aspirin, naproxen) are
recommended because there is a ceiling effect to the analgesia and they do not produce tolerance
or physical dependence; however, there is increased risk for gastrointestinal ulcers, serious
cardiovascular events, hypertension, acute renal failure, and worsening of preexisting heart
failure (Vonkeman & van de Laar, 2010). These adverse effects can be prevented by limiting
NSAID dosage and duration. Acetaminophen and NSAIDs are effective at relieving pain
resulting from a variety of problems including trauma, arthritis, surgery, and cancer (Carr &
Goudas, 1999; Zuckerman & Ferrante, 1998). Treating moderate or severe chronic pain without
opioids is more complicated. Combination therapies can enhance the effects of non-opioid
analgesics, especially when treating neuropathic pain, which is damage or disease affecting the
somatosensory system (Guay, 2001). The most effective adjuvant therapy is tricyclic
antidepressants (Guay, 2001). Tricyclic antidepressants are not FDA-approved for pain
treatment; however, several studies have shown their effectiveness for arthritis, diabetic
neuropathy, postherpetic neuralgia, tension headache, migraine, fibromyalgia, low back pain, and
pelvic pain (Barkin, Schwer, & Barkin, 2007; Rosenquist, 2013). A second adjunctive treatment
is anticonvulsants, which are effective at relieving shooting pain associated with peripheral nerve
damage (Guay, 2001). Anticonvulsants are effective in alleviating the pain associated with
fibromyalgia and neuropathic pain, with some support for use in patients with low-back pain due
to radiculopathy (Attal et al., 2010; Dworkin et al., 2010; Crofford et al., 2005; Tan, Barry,
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Reken, & Baker, 2010). Skeletal muscle relaxants often are prescribed as adjuvant medications
for short-term relief due to the sedative side effects. The long term use of muscle relaxants has
not been shown to be an effective treatment for chronic pain; however, they are superior to
placebo for mild to severe muscle spasms often associated with a variety of pain conditions (See
& Ginzburg, 2008). Finally, topical agents have been utilized when the pain in localized and are
advantageous in that the user can avoid systemic side-effects (Turk, Wilson, & Cahana, 2011).
Topical agents have demonstrated effective pain relief as compared to placebo for neuropathic
pain and musculoskeletal disorders (Mason et al., 2004). These non-opioid pharmacological
options provide health care providers with greater flexibility when treating chronic pain and are
effective at alleviating mild to moderate pain (Guay, 2001).
Interventional treatments. Interventional treatments include anesthetic injection
therapy, surgical intervention, and implantable devices, all with the purpose of locating an
individual’s source of pain and providing pain relief (Turk et al., 2011). Injection therapy
utilizes nerve blocks,which deliver various anesthetics to nerves and muscles to interrupt pain
messages in the body, reduce inflammation, or eliminate the neurons at the site of the pain (Turk
et al., 2011). The most common injection for pain management is an epidural steroid injection,
which is most effective in patients with radiculopathy with prolapsed lumbar disc (i.e., nerve root
damage, which can cause pain in the arms, hands, or feet) and less so in those with non-specific
low-back pain (Chou, Atlas, Stanos, & Rosenquist, 2009; Manchikanti, 2004). The second most
common injection is the facet injection, which includes a long-lasting corticosteroid (e.g.,
triamcinolone or methylprednisolone) and an anesthetic numbing agent (e.g., lidocaine or
bupivacaine; Manchikanti, 2004). There are mixed findings in regard to the effectiveness of
injections, especially for long-term use. A review conducted by Luijsterburg et al. (2007),
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found injections were not shown to be clearly effective for use in lumbosacral radicular
syndrome (i.e., low back pain that radiates into the buttock or down the leg); however, Chou and
colleagues (2009) determined injections are useful in facet joint pain. The general consensus in
the literature is that the use of an injection treatment regimen is most effective for facet joint
pain, discogenic low-back pain, and in radiculopathy with prolapsed lumbar discs (Chou et al.,
2009).
Surgical intervention refers to procedures such as lumbar fusions, artificial disc
replacement, discectomy for radiculopathy with herniated lumbar disc, decompressive
laminectomy for spinal stenosis, and implantation of an interspinous spacer device (Turk et al.,
2011). From 1990 to 2001, there has been an increase in spinal surgeries for chronic pain
patients, with lumbar fusion procedures increasing 220% (Deyo, Gray, Kreuter, Mirza, & Martin,
2005). While the rate of surgeries has increased, the evidence supporting the effectiveness of
spinal surgeries in pain reduction remains poor to fair. Studies have found that there can be
initial significant pain reduction; however, benefits diminish over time, with one study reporting
41% of patients with no change or worsened quality of life approximately five years following
the procedure (DeBerard, Masters, Colledge, Schleusener, & Schlegel, 2001; Fritzell, Hagg,
Wessberg, & Nordwall, 2001). For patients with chronic non-cancer pain, there are no
guidelines that suggest which patients are most likely to benefit from spinal surgery, and as a
result the outcomes on pain reduction are unpredictable.
Another interventional treatment involves the implantation of electrodes or intrathecal
drug delivery devices on or near the spine (Turk et al., 2011). The electrodes act to inhibit pain
signals by stimulating peripheral nerves, which modulate pain (Turk et al., 2011). This
technique has been shown to reduce pain, improve quality of life, reduce the use of analgesics,
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and result in patients returning to work; however, these results are limited to selected patients
with refractory neuropathic pain (Taylor, 2006). Epidural and intrathecal devices provide
targeted drug delivery, which enables patients to experience pain relief with a small fraction of
an oral medication dose (Nance & Meythaler, 1999). Turner, Sears, and Loeser (2007)
conducted a systematic review and concluded that patients typically experience moderate
reductions in pain and improvements in functioning; however, the long-term effectiveness is
unclear. Implantable devices should be considered after oral medication, surgery, and injection
procedures have not provided adequate pain reduction due to the need for routine monitoring,
high cost, and need for replacement and maintenance of devices (Turk et al., 2011).
A less invasive alternative to intrathecal drug delivery devices is transcutaneous electric
nerve stimulation. This technique utilizes electrodes placed on the skin near the spine, which
deliver electrical stimulation to reduce pain through nociceptive inhibition at the presynaptic
level in the dorsal horn, limiting the transmission of pain signals (Nnoaham & Kumbang, 2008).
Systematic reviews and meta-analyses resulted in mixed findings on the effectiveness for
transcutaneous electric nerve stimulation on pain reduction, which in part is due to poor study
methodology (Johnson & Martinson, 2007; Khadilkar, Odebiyi, Brosseau, & Wells, 2008;
Nnoaham & Kumbang, 2008).
Physical, rehabilitation, and psychological interventions. Exercise interventions have
been shown to decrease pain by approximately 30% and improve function by approximately
20% (van Tulder, Malmivaara, Hayden, & Koes, 2007). Exercise interventions also have been
shown to affect work disability status, increasing returns to work (Schonstein, Kenny, Keating,
& Koes, 2003; Oesch, Kool, Hagen, & Bachmann, 2010). One problem with the success of these
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interventions is patient adherence, which potentially can be mitigated through psychological
intervention.
The most common psychotherapeutic techniques utilized for chronic pain patients include
cognitive-behavioral strategies (Turk et al., 2011). Specific strategies commonly employed are
coping techniques, cognitive restructuring, and relaxation techniques. The results of several
meta-analyses and systematic reviews suggest that psychological treatment results in moderate
improvements in pain reduction and physical and emotional functioning (Dixon, Keefe, Scipio,
Perri, & Abernethy, 2007; Henschke et al., 2010; Hoffman, Papas, Chatkoff, & Kerns, 2007;
Jensen & Patterson, 2006; Montgomery, DuHamel, & Redd, 2000; Morley, Eccleston, &
Williams, 1999). Because a portion of patients do not respond to cognitive-behavioral treatment,
a second psychotherapeutic strategy of acceptance-based interventions has been employed for
chronic pain patients. These techniques emphasize acceptance of the pain rather than attempting
to fight or control it; to recognize and accept that the pain is a part of life and cannot be
completely eliminated. This approach utilizes mindfulness and meditation techniques to reduce
stress and pain (Kabat-Zinn, 1990). A systematic review and meta-analysis revealed that
acceptance-based interventions are equivalent in effectiveness to cognitive-behavioral treatment,
and may be a good alternative for those who do not respond to cognitive-behavioral techniques
(Veehof, Maarten-Jan, Schreurs, & Bohlmeijer, 2011).
Integration of physical and psychological treatments into a singular interdisciplinary pain
rehabilitation program results in significant pain reduction (Guzman et al., 2001; Hoffman et al.,
2007; Morley et al., 1999) and a decrease in prescription pain medication usage (Hoffman et al.,
2007). Other studies have reported significant reductions in health care use after rehabilitation
programs (Flor, Fydrich, & Turk, 1992), and reduction in social transfers and benefits (i.e.,
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welfare benefits, sickness benefit, and pensions; Thomsen, Sorensen, Sjogren, & Eriksen, 2002),
which has not been shown to be possible through pharmacological or invasive treatment
(Nachemson, 1992). Additionally, in two of the meta-analyses conducted, results suggest that
the long-term effects on return to work for patients treated in an interdisciplinary rehabilitation
program were superior to those of other active treatments (Flor et al., 1992; Hoffman et al.,
2007).
Complementary and alternative interventions. The most popular complementary and
alternative treatments offered include spinal manipulations, massage therapy, and acupuncture.
These techniques are not commonly associated with conventional medicine; however, research
has demonstrated that these techniques are at least minimally effective in reducing pain (Turk et
al., 2011). Spinal manipulations (i.e., chiropractic adjustments) are most commonly used for
low-back pain. Based on two systematic reviews, researchers concluded that spinal
manipulations are more effective than “placebo” spinal manipulations, bed rest, or traction (Tan
et al., 2007). Massage therapy seems to have benefits for low-back and shoulder pain and
potentially beneficial for fibromyalgia and neck pain (Tan et al., 2007); however, it is difficult to
draw conclusions because of the wide variations in massage techniques. Of all of the
complementary and alternative interventions, acupuncture has the most support for its use with
chronic pain patients. Acupuncture has been shown to be effective for the treatment of chronic
low-back pain (Furlan et al., 2005; Haake et al., 2007; Manheimer, White, Berman, Forys, &
Ernst, 2005; Witt, Ludtke, Wegscheider, & Willich, 2010) with possible pain reduction benefits
for fibromyalgia and neck pain (Gilron & Max, 2001). While acupuncture helps to reduce pain,
it has not been shown to be effective in improving functioning, physically or emotionally (Turk
et al., 2011).
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Flow sheet for Chronic Opioid Therapy: WVU Department of Family Medicine
NEW PATIENTS TO CLINIC:


No opioids written at first visit



Explain process to patients and give information sheet on narcotics prior to check out

PRIOR TO PRESCRIBING OPIOIDS:


Previous records received from provider and reviewed



Urine drug screen



Physical exam and review of diagnostic studies



Diagnosis of pain condition determined



WV Board of Pharmacy review



Refer to Family Medicine psychologists for pain evaluation

PAIN ASSESSMENT (BY PSYCHOLOGIST)




Self-report questionnaires assess:


Quality, intensity, and duration of pain



Functioning affected by pain



Negative cognitions about pain



Fear of activity and movement



Risk for future misuse of opioids



Current behaviors indicating medication misuse



Mood

Clinical Interview


Pain triggers
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Goals for pain and function



Impact of pain on functioning



Pain treatment history



Social and family history



Substance abuse history for patient and family

IF PRESCRIBING OPIOID…


Controlled substance agreement signed



Treatment plan includes non-opioid options (PT, TCA, anti-seizure med, Tai Chi, CBT)



Document plan in chart



All controlled substances scripts printed electronically



No other CNS depressants (i.e, Benzodiazepines or ETOH)



If resident physician, inform attending

PERIODIC ASSESSMENT FOR ALL PATIENTS ON CHRONIC OPIOIDS


Random Drug Screen every 4-6 months or as physician requests



Pain, functioning, mood measures



Verify adherence to all treatment (not solely opioids)



Verify that patient is not receiving opioids from other providers or locations (review
Electronic Medical Records



Board of Pharmacy required at least annually
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Appendix C
Demographics Form
Today’s date:_______________
NAME:_____________________________
Are you: (Circle one)

Single

DATE OF BIRTH:__________________

Married

Number of Children: _____________

Separated

Divorced

AGE:___________

Widowed

How many times have you been married?_________

If married, Spouse’s occupation: _______________________________________________________________
Are you (circle one):

Working

Retired

Disabled

Student

Volunteering

Other_____________

What type of work do you do?_________________________________________________________________
Person to contact in emergency :_______________________

Phone: ______________________________

Who lives with you? ________________________________________________________________________
If we need to contact you, is it OK to call you at home? _____________
Is it OK to leave a message?_________________

Work?______________

If yes, at what number?__________________________

Family Doctor: _____________________________________________________________________________
List of Medications:_________________________________________________________________________
__________________________________________________________________________________________
Reason for visit today? _______________________________________________________________________
How long has pain been a problem for you?______________________________________________________
Which of these techniques have you already tried? How much did it help?
1
2
3
4
5
(none)
(some)
(a lot)
Physical Therapy
Surgery
Medication
Massage
Exercise
Tai Chi/Yoga
Chiropractor
Caffeine use (Circle all that apply):

Coffee

Tea

Soda

No-Doz

Alcohol use: Daily________ Weekly________Monthly_______ How much?______________
Nicotine Use: Cigarettes/day:__________ Packs/day_________ Years Used______________
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Have you ever tried to quit?
Would you like to try to quit?
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Yes________
Yes________

No________
No________

Is alcohol or drug use causing you any problems in your life? Yes_______ No________
Have you ever tried to hurt yourself?
Are there guns in your home?

Yes________ (When?____________________) No______
Yes________ No________

Highest Grade Completed:____________________________________________________________________
Where were you raised?_________________________

Who raised you?________________________

How long have you lived in this area?___________________________________________________________
Was there any violence in your home when you were a child?________________________________________
Do you have a religious affiliation? YES______

NO_____

If yes, how often do you attend church services?___________________________________________________
Are there any cultural or ethnic issues that would be important for me to understand about you? YES_____
NO_____
_______________________________________________________________________________
Have you ever served in the military? YES_______

NO_______

What do you do for fun?______________________________________________________________________
Please place an X in the NOW column for any of the following symptoms you are currently having, and place
an X in the PAST column for any of the symptoms you have had in the past.
NOW
____
____
____
____
____
____
____
____
____
____

PAST
____
____
____
____
____
____
____
____
____
____

Sad Most of the Time
Loss of Energy
Not Enjoying Things
Loss of Sex Drive
Excessive Sleep
Hearing voices in your head
Worry too much
Problems Concentrating
Feeling Shaky
Don’t want to live

NOW
____
____
____
____
____
____
____
____
____
____

PAST
____
____
____
____
____
____
____
____
____
____

Mood Swings
Too Much Energy
Spending Too Much Money
Feeling Nervous
Difficulty with Sleep
Angry Outbursts
Unusual thoughts
Panic attacks
Thoughts you can’t get out of your head
Feeling like you’re being watched or followed

If you could change 3 things about yourself or your situation, what would you pick?
1) Most important: ______________________________________________________________________
2) Next important: ______________________________________________________________________
3) Important:
_______________________________________________________________________
Is there anything else you would like us to know about you or your situation?____________________________
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Appendix D
Short Form-McGill Pain Questionnaire
Some of these words describe your present pain. Please mark an intensity rating for each word. If a word
does not describe your pain, rate it “0” (none). If a word does describe your pain, rate the intensity of that
quality with “1” (mild), “2” (moderate), or “3” (severe). Make your rating by placing a mark in the
appropriate box.
None
Mild
Moderate
Severe
(0)
(1)
(2)
(3)
1. Throbbing
2. Shooting
3. Stabbing
4. Sharp
5. Cramping
6. Gnawing
7. Hot-Burning
8. Aching
9. Heavy
10. Tender
11. Splitting
12. Tiring-Exhausting
13. Sickening
14. Fearful
15. Punishing-Cruel
Mark the intensity of your present pain on the following scale:
No Pain

(0)

Mild

(1)

Discomforting (2)
Distressing

(3)

Horrible

(4)

Excruciating

(5)
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Appendix E
Pain Disability Index
The rating scales below are designed to measure the degree to which several aspects of your life are presently
disrupted by persistent pain. In other words, we would like to know how much your pain is preventing you from
doing what you would normally do, or from doing it as well as you normally would. Respond to each category
by indicating the overall impact of pain in your life, not just when the pain is at its worst.
For each of the 7 categories of life activity listed, please circle the number on the scale which describes the level
of disability you typically experience. A score of 0 means no disability at all, and a score of 10 signifies that all
of the activities in which you would normally be involved have been totally disrupted or prevented by your
pain.
No
Disability
1. Family/Home Responsibilities
This category refers to activities related to the home
or family. It includes chores or duties performed
around the house (e.g., yard work) and errands or
favors for other family members (e.g., driving the
children to school).
2. Recreation
This category includes hobbies, sports, and other
leisure time activities.
3. Social Activity
This category refers to activities which involve
participation with friends and acquaintances other
than family members. It includes parties, theatre,
concerts, dining out, and other social functions.
4. Occupation
This category refers to activities that are part of or
directly related to one’s job. This includes nonpaying jobs such as that of a housewife or volunteer
work.
5. Sexual Behavior
This category refers to the frequency and quality of
one’s sex life.
6. Self-Care
This category includes activities which involve
personal maintenance and independent daily living
(e.g., taking a shower, getting dressed, etc.).
7. Life-Support Activity
This category refers to basic life-supporting
behaviors such as eating, sleeping, and breathing.

Total
Disability

0

1

2

3

4

5

6

7

8

9

10

0

1

2

3

4

5

6

7

8

9

10

0

1

2

3

4

5

6

7

8

9

10

0

1

2

3

4

5

6

7

8

9

10

0

1

2

3

4

5

6

7

8

9

10

0

1

2

3

4

5

6

7

8

9

10

0

1

2

3

4

5

6

7

8

9

10
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Appendix F

Pain Catastrophizing Scale
Everyone experiences painful situations as some point in their lives. Such experiences may include headaches, tooth pain, joint or muscle pain.
People are often exposed to situations that may cause pain such as illness, injury, dental procedures, or surgery.
We are interested in the types of thoughts and feelings that you have when you are in pain. Listed below are 13 statements describing different
thoughts and feelings that may be associated with pain. Using the following scale, please circle the degree to which you have these thoughts and
feelings when you are experience pain.
Not
To a
To a Moderate
To a
All the
at All
Slight Degree
Degree
Great Deal
time
1. I worry all the time about whether the pain will end.
0
1
2
3
4
2.

I feel I can’t go on.

0

1

2

3

4

3.

It’s terrible and I think it’s never going to get any better.

0

1

2

3

4

4.

It’s awful and I feel that it overwhelms me.

0

1

2

3

4

5.

I feel I can’t stand it anymore.

0

1

2

3

4

6.

I become afraid that the pain will get worse.

0

1

2

3

4

7.

I keep thinking of other painful events.

0

1

2

3

4

8.

I anxiously want the pain to go away.

0

1

2

3

4

9.

I can’t seem to keep it out of my mind.

0

1

2

3

4

10. I keep thinking about how much it hurts.

0

1

2

3

4

11. I keep thinking about how badly I want the pain to stop.

0

1

2

3

4

12. There’s nothing I can do to reduce the intensity of the pain.

0

1

2

3

4

13. I wonder whether something serious may happen.

0

1

2

3

4
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Appendix G
Tampa Scale for Kinesiophobia
Please read each of the following statements and mark the number that better represents your feelings.

Strongly
Disagree

Somewhat
Disagree

Somewhat
Agree

Strongly
Agree

1.

I’m afraid that I might injure myself if I exercise.

1

2

3

4

2.

If I were to try and overcome it, my pain would increase.

1

2

3

4

3.

My body is telling me I have something dangerously
wrong.

1

2

3

4

4.

My pain would probably be relieved if I were to exercise.

1

2

3

4

5.

People aren’t taking my medical condition seriously
enough.
My accident has put my body at risk for the rest of my
life.

1

2

3

4

1

2

3

4

6.
7.

Pain always means I have injured my body.

1

2

3

4

8.

Just because something aggravates my body does not
mean it is dangerous.

1

2

3

4

9.

I am afraid that I might injure myself accidently.

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

10. Simply being careful that I do not make any unnecessary
movements is the safest thing I can do to prevent my pain
from worsening.
11. I wouldn’t have this much pain if there weren’t something
potentially dangerous going on in my body.
12. Although my condition is painful, I would be better off if
I were physically active.
13. Pain lets me know when to stop exercising so that I don’t
injure myself.
14. It’s really not safe for a person with a condition like mine
to be physically active.
15. I can’t do all the things normal people do because it’s too
easy for me to get injured.
16. Even though something is causing me a lot of pain, I don’t
think it’s actually dangerous.
17. No one should have to exercise when s/he is in pain.

PREDICTING OPIOID PRESCRIBING BEHAVIOR

109
Appendix H

Screener and Opioid Assessment for Patients with Pain-Revised
Never

Seldom

Often

1

Sometimes
2

3

Very
Often
4

1. How often do you have mood swings?

0

2. How often have you felt the need for higher doses of medication to treat your pain?

0

1

2

3

4

3. How often have you felt impatient with your doctors?

0

1

2

3

4

4. How often have you felt that things are just too overwhelming that you can’t handle them?

0

1

2

3

4

5. How often is there tension in the home?

0

1

2

3

4

6. How often have you counted pain pills to see how many are remaining?

0

1

2

3

4

7. How often have you been concerned that people will judge you for taking pain medication?

0

1

2

3

4

8. How often do you feel bored?

0

1

2

3

4

9. How often have you taken more pain medication than you were supposed to?

0

1

2

3

4

10. How often have you worried about being left alone?

0

1

2

3

4

11. How often have you felt a craving for medication?

0

1

2

3

4

12. How often have others expressed concern over your use of medication?

0

1

2

3

4

13. How often have any of your close friends had a problem with alcohol or drugs?

0

1

2

3

4

14. How often have others told you that you had a bad temper?

0

1

2

3

4

15. How often have you felt consumed by the need to get pain medication?

0

1

2

3

4

16. How often have you run out of pain medication early?

0

1

2

3

4

17. How often have others kept you from getting what you deserved?

0

1

2

3

4

18. How often in your lifetime have you had legal problems or been arrested?

0

1

2

3

4

19. How often have you attended an AA or NA meeting?

0

1

2

3

4

20. How often have you been in an argument that was so out of control that someone got hurt?

0

1

2

3

4

21. How often have you been sexually abused?

0

1

2

3

4

22. How often have others suggested that you have a drug or alcohol problem?

0

1

2

3

4

23. How often have you had to borrow pain medications from your family or friends?

0

1

2

3

4

24. How often have you been treated for an alcohol or drug problem?

0

1

2

3

4

